Development of fast, reliable and automated isolation and fractionation methods for nanosized subpopulations of human biomacromolecules by Multia, Evgen
Department of Chemistry 
Faculty of Science
University of Helsinki 
Finland
Development of fast, reliable and 
automated isolation and 
fractionation methods for 
nanosized subpopulations of 
human biomacromolecules  
Evgen Multia
DOCTORAL DISSERTATION 
To be presented for public examination with the permission of the Faculty of 
Science of the University of Helsinki, in Chemicum Auditorium A110, A. I. 








Reviewers Professor Jonas Bergquist





Department of Life Technologies
University of Turku
Finland
Opponent Ikerbasque Research Professor 
Juan M. Falcón-Pérez
Center for Cooperative Research 
in Biosciences (CIC bioGUNE)















This doctoral thesis describes the development of fast, reliable and automated isolation and 
fractionation methods for nanosized subpopulations of human biomacromolecules. The focus 
of the study was on subpopulations of lipoproteins and extracellular vesicles (EVs) that are 
important in the detection of different diseases, such as atherosclerotic cardiovascular 
diseases and cancer, and may even possess therapeutic potential. In the thesis,
immunoaffinity chromatography (IAC) with selective antibodies immobilized on the monolithic 
disk columns were utilized for the selective isolation of biomacromolecules from human 
plasma, while asymmetrical flow field-flow fractionation (AsFlFFF or AF4) was able to 
fractionate relevant subpopulations of biomacromolecules (e.g., small dense low-density 
lipoproteins, exomeres, and exosomes) from the isolates. Continuous flow quartz crystal 
microbalance (QCM) and partial filling affinity capillary electrophoresis (PF-ACE) were 
employed to study the affinity of the interactions between the antibody and lipoproteins. 
The first step was to develop a method to study interactions between antibody and lipoproteins 
to select a high affinity antibody useful for the isolation of lipoprotein subpopulations by IAC.
The interaction data obtained with PF-ACE was analyzed to determine the heterogeneity of 
the interactions with adsorption energy distribution calculations, while the QCM data was 
processed with interaction maps. The affinity constants obtained with QCM and PF-ACE 
agreed well with each other.
Next, the IAC methods were developed to capture EVs of different cellular origins from human 
plasma using anti-CD9 monoclonal antibody (mAb), while anti-CD61 mAb was exploited to 
capture platelet-derived EVs. The anti-apolipoprotein B-100 (anti-apoB-100) mAb was 
exploited to immunocapture apoB-100 containing lipoproteins. The anti-apoB-100 mAb was
also characterized by the PF-ACE and QCM studies. Appropriate elution conditions were 
found for the IAC methods, which has often been an issue with magnetic beads-based 
immunoaffinity methods. 
Since IAC allowed selective isolation of EVs and lipoproteins, a size-based separation to their 
subpopulations with AsFlFFF was introduced as a successive step. This enabled additional 
characterization of subpopulations by nanoparticle tracking analysis, western blotting, electron 
microscopy, capillary electrophoresis coupled with laser-induced fluorescent detection, zeta 
potential measurements, as well as free amino acids and glucose analysis with hydrophilic 
interaction liquid chromatography-tandem mass spectrometry.
Finally, IAC was successfully on-line coupled to AsFlFFF, resulting in quick and automated 
isolation and fractionation of the subpopulations of EVs and lipoproteins. The constructed IAC-
AsFlFFF system was able to process reliably 18–38 samples in 24 h with only minor operator 
involvement, resulting in highly reproducible and gentle fractionation of EV subpopulations in 
the size range of exomeres and exosomes.
Polymeric monolithic disk columns were utilized for the first time for the IAC-based isolation 
of EVs and their subpopulations from human plasma, and for the detection of exomeres in 
CD9+ EVs and CD61+ platelet-derived EVs from human plasma samples. The results
demonstrated that CD61+ EVs are potentially taking part in gluconeogenesis based on free 
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Human biomacromolecules such as extracellular vesicles (EVs) and lipoproteins are 
heterogeneous nanosized particles that have a crucial role in several physiological 
and pathological processes, and hence useful in therapeutic and diagnostic 
applications. EVs have shown potential in cancer diagnosis, and as well as in the 
diagnosis of angiogenesis, immune response, cardiovascular, and 
neurodegeneration related diseases.1 In addition, EVs have the ability to reach
specific cells by passing e.g., inter-endothelial junctions or the blood-brain-barrier,
and release the cargo inside these cells2,3 leading to their therapeutic potential in e.g., 
drug delivery. In addition, EVs of specific origin, such as platelet-derived EVs, have 
been found to take part in many diseases.4–6 These EVs are involved in the immune 
system, inflammation, hemostasis, and thrombosis together with platelets,7,8 and hold 
potential to be utilized in therapeutics and diagnostics of various diseases e.g.,
bleeding disorders, cancer, cardiovascular-related diseases, and wound healing.8–11
Lipoproteins, on the other hand, play an important role in the development of 
atherosclerosis. Atherosclerosis develops in the primary phase when low-density 
lipoprotein (LDL) is retained and accumulated to arterial walls.12,13 But even within 
LDL there are subclasses, such as small-dense LDL (sdLDL), that have been found 
to associate with metabolic disorder,14 and have an even higher atherogenic effect 
compared to LDL subclasses with bigger size.15 New advanced methods and 
techniques are needed to isolate this kind of specific subclasses/populations that are 
currently not feasible with conventional isolation techniques from complex biofluids.
Multiple limitations of conventional isolation techniques, such as density-based 
ultracentrifugation (UC), limit their use, but it is also possible to utilize size-, charge-,
and affinity-based techniques. Nonetheless, there is a great need for new time-
effective, easy-to-operate methods/techniques that have control of the final product. 
In addition to purity, it is also important to preserve the integrity of the 
biomacromolecules that tend to be fragile. For more complex biomacromolecules 
such as EVs, even combination and hyphenation of multiple techniques are
necessary to produce subpopulations of adequate purity. The conventional 
techniques (e.g. UC) have large intra- and inter-batch variations, especially when 
isolating EVs.16 Additionally, the UC is expensive, time-intensive, and tedious due to
a large amount of manual labor, and has been known to contaminate the EV isolates 
with lipoproteins and other proteins. This is unacceptable in the therapeutic
applications where the isolation technique should be able to handle complex biofluids, 
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scalable, reliable, and automated, and produce reproducible subpopulations of known 
characteristics.16,17
Immunoaffinity chromatography (IAC) has the advantage of being selective for 
specific analytes due to the high affinity of antibodies towards the antigen. The IAC 
with polymeric monolithic columns can overcome the limitations of other affinity-
based methods (e.g. magnetic beads) to handle complex biofluids, such as plasma. 
The polymeric monolithic columns offer a wide pH range stability and reusability.
Quartz crystal microbalance (QCM) and partial filling affinity capillary electrophoresis 
(PF-ACE) are useful tools for screening the suitable ligand candidates and obtaining 
information on the interactions between the antibody and the analytes. The size-
based separation of biomacromolecules by asymmetrical field-flow fractionation 
(AsFlFFF) gives flexibility with modifiable and optimizable cross-flow that size-
exclusion chromatography (SEC) does not have. In AsFlFFF the fractionation 
parameters can be modified even between runs, while in SEC this would require 
changing the entire column. Moreover AsFlFFF handles biomacromolecules in a 
gentle way due to the lack of shear forces from the stationary phase present in the 
SEC, thus preserving their fragile integrity. The buffer can be exchanged in the 
AsFlFFF to formulation buffer, which is especially important when producing fractions
of biomacromolecules for therapeutic purposes. The AsFlFFF has been also useful 
in discovering new subpopulations of EVs such as exomeres.18
The main objective of this doctoral thesis was to develop fast and easily automated 
methods/techniques for the reliable isolation of subpopulations of biomacromolecules 
(EVs and lipoproteins) from minute human plasma volume and to study specific 
antibody-antigen interactions needed for the isolation.
17 
 
The specific aims of the thesis were:
To exploit PF-ACE and QCM to study interactions between anti-apoB-100 
monoclonal antibody and apoB-100 containing lipoprotein subpopulations.
(Paper I)
To develop a monolithic IAC method to isolate platelet-derived (CD61+) EVs
in the size range of exomeres and exosomes. (Paper II)
To compare the monolithic IAC disks immobilized with anti-CD9 and anti-
CD61 to UC and SEC as EV isolation techniques. (Paper III)
To utilize AsFlFFF coupled with multiple detectors to study and fractionate 
exomere and exosome sized EVs pre-isolated with IAC. (Papers II-IV)
To obtain lipoprotein-free EV subpopulation isolates. (Papers II-IV)
To develop an automated on-line IAC-AsFlFFF system for isolation and 
fractionation exomere and exosome sized EVs, and apoB-100 containing 
lipoprotein subpopulations. (Paper IV)
To study metabolite (amino acid and sugar) composition of CD9+ and CD61+
EV subpopulations in the size range of exomere and exosome. (Paper IV)
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2. BACKGROUND TO THE WORK 
2.1  Modern techniques in the isolation, separation, and 
fractionation of human biomacromolecules 
 
This section describes current modern techniques in the isolation, separation, and 
fractionation of human biomacromolecules. Biomacromolecules can be isolated with 
different techniques (Figure 1), e.g., with density-based techniques such as 
ultracentrifugation,19–22 affinity-based techniques (magnetic particles23–25 and affinity 
chromatography26), charge-based techniques  (cyclical electrical field-flow 
fractionation,27,28 ion-exchange,29,30 ion concentration polarization,31 
electrophoresis,32,33 and dielectrophoresis34,35), size-based techniques (field-flow 
fractionation,36–38 filtration,39–44 deterministic lateral displacement pillar arrays,45–47 
size-exclusion chromatography (SEC),48–51 and viscoelastic microfluidic systems52), 
microfluidic platforms,53 acoustic trapping techniques,54–56 precipitation,57,58 and 
hydrophilic interaction chromatography59,60 from a variety of different body fluids.   
 
Figure 1. Most common techniques utilized in the isolation biomacromolecules (EVs) 
and the expected time needed for the isolation. Adapted from  61. 
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Due to overlapping sizes and densities of the biomacromolecules (e.g., in the case 
of lipoproteins and extracellular vesicles, and retroviruses, Figure 2), it is often not 
possible to isolate pure subpopulations of human biomacromolecules with a single 
technique, thus requiring a combination of techniques.36,37,62–64 The “golden standard” 
technique for the isolation of many biomacromolecules is density-based separation 
with ultracentrifugation. However, the centrifugation has many limitations, such as 
high cost, time consuming, need for skillful operators and tedious manual labor, 
prone to batch to batch irreproducibility, and production of a lot of waste. Accordingly 
it is obvious that there is a need for more automated, fast, selective, and scalable 
modern techniques. 
 
Figure 2. Size and density of different subtypes of EVs, lipoproteins, and 




Fast and selective isolation of biomacromolecules can be achieved with affinity-
based separation techniques such as affinity chromatography. In the affinity 
chromatography the binding ligand is immobilized to the stationary support.68,69 The 
ligand utilizes biological interactions to selectively capture its counterpart (e.g., 
enzyme captures substrate, antibody captures antigen in immunoaffinity, or vice 
versa).68,70,71 Most commonly, the bound biomolecules can be released with non-
specific elution by changing the pH of the mobile phase.68,70 The first specific 
isolation of an enzyme and its substrate date as early as 1910, when Emil 
Starkenstein was purifying α-amylase.70,72,73 The field continued to evolve in the 
1930s with purification of antibodies.72,74–76 In the 1960s other important 
biomacromolecules such as transfer RNA,77 nucleotides,78 strands of nucleic acid,79
and nuclease80 were purified. After the first appearance of the term affinity 
chromatography in 1968,80 more than 50,000 papers have been published including
this term, with the most active growth period being from 1968-90.26
Different support materials can be used in the affinity chromatography, e.g., agarose, 
cellulose and other carbohydrate supports, silica, and a variety of organic polymers 
such as polymethacrylate and polystyrene.70 The correct selection of support
material is crucial for the isolation of biomacromolecules, since all of the materials 
have some advantages and disadvantages. Agarose and organic polymers have a
wide operating pH range and biocompatibility that for example silica-based supports
do not have without the chemical modification of their surface. However, opposite to 
agarose, silica-based materials have mechanical stability that can be utilized in high 
performance liquid chromatography (HPLC).26,70 Over the last 20 years, monolithic
supports have increased their popularity in the affinity chromatography and have 
significant advantages in isolation of biomacromolecules compared to particulate 
supports.70,81–85 Especially polymer-based monoliths (ethylene glycol dimethacrylate 
(EDMA) and glycidyl methacrylate (GMA)), offer good separation efficiency, 
permeability, low back pressures, and can be utilized for isolation of e.g., viruses 
and DNA.70,86–91
The most applied form of bioaffinity chromatography has been immunoaffinity 
chromatography (IAC).26,92–94 Due to strong interactions between the antibody and 
antigen, it is possible to isolate molecules even from complex biofluids.70,95–102 For 
example, combining silica monoliths with the IAC has resulted in successful isolation 
of CD9+ EVs from human serum samples of lung cancer patients.103 In this system,
monoliths immobilized with antibodies were placed in the pipette tip, and the system 
could isolate one sample/tip in 30 minutes. In addition, even the 96-well plate format 
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including the combination of the IAC and monoliths has been used to isolate 
transferrin from plasma samples up to 20 times/monolith.104
The concept behind field-flow fractionation (FFF) was first published in 1966105 by 
J.C. Giddings for the separation of macromolecules and colloids. The first publication
was followed by many variations of FFF: such as electrical, flow, sedimentation, and 
thermal. The flow field-flow fractionation (FlFFF) variation (published in 1976106,107)
has become the most popular and versatile variant. In the FlFFF the cross flow 
perpendicular to the main flow creates the hydrodynamic field that results in 
separation of macromolecules based on the differences in their diffusion 
coefficients.108,109 The FlFFF has an advantage in being able to utilize almost any 
solution as a mobile phase, and can be divided into symmetrical and asymmetrical
(AsFlFFF/AF4) subtechniques. The AsFlFFF, first published in 1986,110,111 was 
actively developed during the following years, and has become the most popular 
subtechnique since.
The channel in the AsFlFFF consists of two plates separated by a spacer. A 
permeable membrane at the bottom plate is called accumulation wall.66,112 The 
macromolecules are carried by a parabolic flow profile from the channel to detectors 
and biomacromolecules get separated by the perpendicular cross-flow. The size-
based separation of biomacromolecules by the AsFlFFF is more flexible compared to 
e.g., SEC due to easily modifiable and optimizable cross-flow. Modifications can be 
done even between runs, while in the SEC this would require changing the entire
column.66 The small biomacromolecules (high diffusion coefficient) remain further 
from the bottom of the channel, while larger biomacromolecules stay closer to the 
accumulation wall. Thus in normal mode, smaller biomacromolecules arrive first to 
the detectors followed by larger ones that is opposite to the order of arrival in the 
SEC.66 The advantage of the AsFlFFF for the separation of biomacromolecules is its
gentle fractionation, due to lack of shear forces from stationary phase (present in the 
SEC) deteriorating the fragile biomacromolecules. With the AsFlFFF it is also possible 
to exchange buffer to formulation buffer, which is important for fractionation of 
biomacromolecules for therapeutic purposes.66 The disadvantage of the AsFlFFF 
might be the dilution of the samples, however this is also the case with the SEC. 
Another limiting factor, when large volumes need to be processed, might be small 




The AsFlFFF has been extensively utilized to study different biomacromolecules such 
as bovine serum albumin (BSA),113 DNA,114 EVs,18,36,37,112,115–119 ferritin,120
globulins,121 lipoproteins,122 liposomes,123,124 plasmids,125 ribosomes,126 and 
viruses.114,120 The EVs have been commonly fractionated utilizing 10 kDa regenerated 
cellulose membrane and a 350 μm spacer.66 Zhang et al. 18 discovered an EV
subpopulation called exomere utilizing the AsFlFFF in 2018.
Capillary electromigration techniques consist of capillary electrophoretic techniques 
and electrically driven capillary chromatographic techniques, depending on 
separation principles. In some cases, these principles are overlapping. These
techniques have advantages in high speed, separation selectivity and efficiency, low 
amount of sample and reagents needed, mass sensitivity, and applicability to 
microchannel structures.127–129 Many techniques have been especially useful for the
separation and study of biomacromolecules.130–139 However, the inner wall of fused 
silica capillary often need to be modified to prevent unwanted adsorption of analytes
and sample matrix components, and to eliminate or control electro-osmotic flow.140–
146 This can be done by masking silanol groups of the capillary by coatings (dynamic 
or covalent), ionic strength, and extreme pH of background electrolyte (BGE).138,147–
149 Polymeric coatings often also increase the repeatability and efficiency of the 
separation of biomacromolecules.138,149–153
In partial filling affinity capillary electrophoresis (PF-ACE) it is possible to analyze 
samples without immobilizing the ligand, and it also consumes less sample and 
reagents compared to traditional affinity chromatography. PF-ACE provides relatively 
fast analysis, and in many cases does not require pre-purified samples.154,155 The PF-
ACE has been successfully utilized to estimate binding constants of complexes154–158
of different biomacromolecules such as lipoproteins.135,137,138,159 PF-ACE combined 
with adsorption energy distribution (AED) calculations offers additional information on
the strength and heterogeneity of the interactions.160–165
Binding studies can also be conducted with optical or acoustic biosensors. The first 
enzyme electrode-based biosensor was introduced by L.C. Clark already in 1962.166
Surface plasmon resonance (SPR) is an optical biosensor with mass sensitivity of 
pg/mm2, while quartz crystal microbalance (QCM) has a mass sensitivity of 
fg/mm2.167–169 In addition to high mass sensitivity, the QCM can sense changes in 
viscoelastic properties and charges of complexes, and allows the possibility to study 
cell adhesion. QCM can elucidate interactions from weak to high affinity133,170 and it 
can be utilized to study the antibody-antigen interactions. With the QCM it is also 
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possible to study very large biomacromolecules and lipid membranes, viruses, 
bacteria, and even whole cells.171–174
The focus of my study was to develop new methods to isolate, separate, and 
fractionate pure subpopulations of biomacromolecules, applicable for therapeutic and 
diagnostic purposes. The emphasis was given to immunoaffinity-based methods due 
to their selectivity, the size-based fractionation with the AsFlFFF, and the charge-
based separation with CE. Combined methods utilizing different separation principles 
were needed due to heterogeneity and overlap of the biomacromolecule
subpopulations in their sizes and densities (Figure 2). Obtaining pure subpopulations 
of biomacromolecules is important because of the disease promoting nature of 
specific subpopulations over others. Information on the concentration levels and the 
composition of the subpopulations can be beneficial for prevention and early 
detection of different diseases. In addition, subpopulations with high purity can be 
utilized e.g., in targeted drug delivery.
2.2 Lipoproteins
 
The main function of lipoproteins is to transport cholesterol, triglycerides, and 
phospholipids in circulation and other extravascular body fluids. Major lipoprotein 
subpopulations include high-density lipoprotein (HDL), LDL, lipoprotein(a) (Lp(a)),175
intermediate-density lipoprotein (IDL), very-low-density-lipoprotein (VLDL), and 
chylomicrons. Their structures, sizes, and densities are collected in Figures 2 and 3.
In addition, the lipoproteins have integrated apolipoproteins (e.g., A, B-100, C, E, and 
J) that are involved in metabolism and binding of the lipoproteins to receptors for 
uptake and release.176,177 For example, LDL contains 80 % lipids and 20 % protein 
called apolipoproteinB-100 (apoB-100), which is the major apolipoprotein found in the 
LDL. ApoB-100 is a very hydrophobic biomacromolecule of a size of 512 kDa that is
synthesized in the liver.178,179 Targeting the apolipoproteins in affinity chromatography 





Figure 3. Major lipoprotein subpopulations in human plasma and their properties.  
 
Lipoproteins play an important role in the development of atherosclerosis. The 
atherosclerosis develops when LDL is retained and accumulated to arterial walls.12,13 
But even within LDL there are subclasses, such as small dense LDL (sdLDL), that 
have been found to associate with metabolic disorder,14 and have an even higher 
atherogenic effect compared to other larger LDL subclasses.15 However, in the 
formation of atherosclerosis, not only the size of the LDL matters, but also its 
concentrations.180  High concentrations in the blood lead to higher accumulation 
probability on the intima walls. After accumulation, the LDL can undergo changes due 
to enzymatic activity and oxidation, leading to aggregation and fusion.181 
Subsequently macrophages form atherogenic foam cells,182 which together with 
inflammation, contribute to the progression of the disease.183,184 Highly atherogenic 
and proinflammatory LDL complexes have often undergone desialylation, obtained 
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negative charge, and oxidized.15 The sdLDL has a favorable size for penetrating the 
arterial wall in addition to prolonged circulation time that increases the probability for
modifications of the sdLDL particle.15,185,186 Cardiovascular diseases (CVDs) have 
been shown to correlate with sdLDL and elevated sdLDL cholesterol.187–191 It has 
been also demonstrated that sdLDL cholesterol is a better biomarker compared to 
total LDL cholesterol for coronary heart disease (CHD) in nondiabetic, prediabetic, 
and type 2 diabetic individuals.192–194 In addition to atherosclerosis, the elevated 
sdLDL concentrations have been linked to metabolic syndrome, diabetes, 
dyslipidemia, and even to chronic kidney disease.195–199
2.2.1 LDL subclasses
LDL can additionally be subdivided into 4 subclasses (Table 1), of which small LDL 
III and very small LDL IV200,201 can be considered sdLDL. However, direct comparison 
of the subclasses and their characteristics among different isolation methods is 
problematic.  LDL III is, for example, defined with UC methods to have a density of 
1.028-1.060 g/mL, with a stricter limit being 1.028-1.044 g/mL, since LDL IV has been 
considered to start from 1.044-1.060 g/mL. Based on electrophoretic mobilities 
measured with gradient gel electrophoresis the size of sdLDL has been determined
to be 22-25.74 nm, where 22-24.1 nm was the size limit of LDL IV and 24.2-25.5 nm 
that of LDL III. Similar size ranges have also been found with HPLC gel filtration, 
where LDL III was 20.7-23 nm and 16.7-20.7 nm for LDL IV. With ion mobility 
measurements and NMR, the size of sdLDL has been attributed to a size range of 
18-21 nm, but direct comparisons to the gradient gel electrophoresis is not possible.15
It has been shown that for sdLDL it takes a longer time before it is cleared from the 
circulation via LDL receptor.202,203 In addition to the longer circulation times, modified 
LDL particles (electronegative, desialylated, glycated, and oxidized) have an 
increased atherogenicity due to increased aggregation and complex formation
probability.204,205 The sdLDL particles are more glycated and more susceptible to 
oxidation due to their different lipid composition and lower concentrations of vitamins 
that have antioxidative properties. The desialylation of the sdLDL increases the time 
of attachment to the arterial wall.206–210
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Table 1. Characteristics of the LDL subpopulations based on density, size, and 














































26.0–28.5 25.5–26.4 24.2–25.5 22.0–24.1
HPLC – gel filtration216
[nm] 25.5–28.6 23–25.5 20.7–23.0 16.7–20.7
DLS217
[nm] 21.5 ± 0.8 20.3 ± 1.1
Ion mobility218
[nm]
21.9–23.8 21.1–21.9 20.17–21.1 18.0–20.17
NMR219,220
[nm] 21.3–22.7 19.8–21.2 18.3–19.7 NANMR221





2.3 Subpopulations of extracellular vesicles
 
Extracellular vesicles (EVs) are heterogeneous populations of nanosized membrane-
enclosed particles (30-5000 nm) released by most cell types that do not replicate.224
EVs can be found in cellular microenvironment and the circulation225, as well as in 
amniotic fluid, breast milk, cerebrospinal fluid, feces, saliva, semen, and urine.226
Ectosomes (e.g., micro- and large vesicles, and microparticles) are EVs of ~50-1000 
nm that bud out from the plasma membrane, while exosomes (~50-150 nm) are EVs 
of endosomal origin1,65, making size-based differentiation of EV subclasses in the 
isolates highly challenging due to size overlap. Exomeres (~30-50 nm) are a newly 
discovered particle type18 that do not have a lipid bilayer, and still unknown 
biogenesis. However, the results suggest that the biogenesis is associated with the 
cell’s metabolism since the inner cargo of exomeres has been found to contain 
proteins from endoplasmic reticulum, microtubules, and mitochondria that are 
involved in glycolysis and mTORC1 metabolic pathways.18,227 Biogenesis and size 
ranges of different EVs subtypes are depicted in Figure 4.
The biogenesis of the exosomes involves inward budding of endosomal membranes 
inside multivesicular bodies,226–228 which also store229 the exosomes before they are 
released outside. The secretion outside the cell happens when the multivesicular 
bodies merge with the plasma membrane and release the exosomes outside in a 
process called exocytosis.226
The biogenesis of microvesicles or ectosomes on the other hand involves budding 
from the surface of the plasma membrane, but the microvesicles may still have a
different membrane composition compared to the surface, indicating that the 
biogenesis is not a random event, and that some regulation of the process may take 
place.226,229 Since the size ranges of the exosomes (Figure 5) and the microvesicles 
overlap in the region of 50-150 nm, the differentiation of these EVs with only density-
and size-based techniques is not possible.66 Selective isolation of the EVs of the 
exosomal size range by affinity chromatography should target common exosomal




Figure 4. Size-based classes of extracellular vesicles and their biogenesis. Exomere 
is a newly discovered particle with still unknown biogenesis. Larger vesicles 
(oncosome, migrasome, exophers) also have unknown biogenesis. The bioactive 
cargo material of EVs can be from cytoplasm, endoplasmic reticulum, Golgi, 
mitochondria, nucleus, and plasma membrane depending on their cellular origin. 
Adapted from 227,228. 
 
Exosomes and EVs in general, isolated for diagnostic purposes, do not need to be 
of high purity, since the primary goal is to obtain sufficient amount of the biomarker 
to enable detection or quantification. For therapeutic purposes such as cellular 
programming, drug delivery, or immunotherapy it is important to have intact, pure, 
and well-defined subpopulations. EVs carry nucleic acids (RNAs), mediator 
molecules, and other metabolites to cells and release the cargo upon internalization 
by the cell,230 and in this way take part in cell-to-cell communication.230 The cargo 
provides a signature of the cell that the EVs originated from, and if this cell is 
pathologic, it can possibly be detected from the EVs.226 Thus, cancer-associated 
material carried by the EVs can be utilized for the development of non-invasive 
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diagnosis and prognosis of tumor progression and stage of cancer.65,231 As one 
potential option to stop the progression of cancer, it has been suggested that tumor-
derived EVs could be removed from the patient.232 However, EVs are not only limited 
to the cancer diagnosis, as they also have diagnostic potential for angiogenesis, 
immune response, cardiovascular, and neurodegeneration-related diseases.1 The 
therapeutic potential of EVs relies on their ability to reach specific cells by passing 
e.g., inter-endothelial junctions or the blood-brain-barrier, and release the cargo 
inside these cells.2,3 
 
 
Figure 5. Structure and cargo of an exosome. Adapted from 1. 
 
2.3.1 Platelets and platelet-derived extracellular vesicles 
 
The main function of platelets is to take part in hemostasis and thrombosis, but they 
are also involved in innate and adaptive immunity, regulation of inflammation, 
nervous system-related diseases, and cancer. Platelets are non-nucleated particles 
of 2-5 μm that may carry granule structures ( - and - granules), lysosomes, 
mitochondria, and open canalicular system.233–236 The multivesicular bodies are the 
source of origin for - granules, while - granules and lysosomes originate from late 
endosomes, and upon platelet activation - and - granules release their content by 
fusing to the surface of the platelet.237–239 Platelet surface proteins such as CD9, 
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CD63 (tetraspanins), CD41/61 (integrin IIb 3),and glycoprotein VI are also found in
the - granules.239
Activated and aging platelets release platelet-derived EVs, which also contain heat 
shock proteins, integrin CD41/61, as well as tetraspanins CD9, CD63, and 
CD81.7,240–243 Platelet-derived EVs work together with platelets in coagulation, and 
they are by concentration one of the most abundant EVs in human blood with even 
further concentration increase after platelets get activated.7,244–246 They are involved 
in multiple physiological and pathological conditions such as autoimmune diseases, 
angiogenesis and CVD, cancer, cellular communication, hemostasis and 
thrombosis.7,240 Thus the therapeutic and diagnostic potential of platelet-derived EVs 
could be e.g., in bleeding disorders, cancer, cardiovascular-related diseases, and 
wound healing.8–11
Exosome-sized platelet-derived EVs share common protein markers and proteome
with - granules, leading to a hypothesis that platelet -granules are the source of 
platelet-derived EVs.7,245,247,248 Different compositions of lipid mediators or 
mitochondrial proteins of larger platelet-derived EVs indicate that they are separate
populations with different functions compared to exosome-sized platelet-derived 
EVs.248 The negative surface charge of platelet-derived EVs is due to 
phosphatidylethanolamine and phosphatidylserine.249 The cargo of platelet-derived 
EVs depends on the environment of the platelet that the EVs originated from, but 
usually they have been found to contain chemokines, cytokines, RNAs, as well as 






Immunoaffinity chromatography (IAC), asymmetrical flow field-flow fractionation 
(AsFlFFF/ AF4), capillary electromigration techniques, and continuous flow quartz 
crystal microbalance (QCM) were the main techniques employed in this thesis (Figure 
6). Kinetic affinity studies of the QCM were complemented with rate constant 
distribution calculations or interaction maps, while adsorption energy distribution 
calculations were utilized for equilibrium affinity studies with the CE. 
 
Figure 6. Techniques and antibodies utilized in the thesis. * Lipoproteins or EVs were 
pre-isolated with the IAC.  
 
3.1  Immunoaffinity chromatography with monolithic 
columns 
 
IAC is an affinity-based liquid chromatographic (LC) technique, where a target antigen 
(analyte) is bound to an antibody (ligand), usually immunoglobulin G (IgG).253 In the 
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IAC, the antibody binds in specific and reversible manner to an epitope84 of the
antigen enabling the isolation and enrichment of antigen even from complex sample 
matrices such as cell culture medium, urine, serum, or plasma.26,70,87,88,254,255 The 
specificity of an antibody to an antigen is determined by its type, e.g., monoclonal 
antibodies (mAb) recognize single epitopes, while polyclonal antibodies (pAb) 
recognize can recognize several different epitopes. This is because the pAbs are a
mixture of antibodies from different B cells, while the mAbs are produced from a clone 
derived from a single B cell. The mAbs tend to also be more expensive, but have a
higher concentration of antibodies specific towards the wanted epitope,84,256 being,
e.g., more suitable for the isolation of highly specific populations of particles 
containing the antigen.  
In reversible IAC binding process, an antigen-antibody ( − ) complex is formed 
between the affinity ligand ( ) and the analyte ( ). The binding and dissociation is 
described by association ( ) and dissociation ( ) constants, while association 
equilibrium rate constant ( ) of the process can be calculated by equation (1),=  =  [ ][ ][ ] =      (1) 
where [ - ], [ ], and [ ] are the concentrations of the analyte-ligand complex,
analyte, and ligand. is the dissociation equilibrium rate constant and it has a
reciprocal relationship to . The process consists of injection of the sample to the 
support with immobilized antibody, washing away the compounds not retained by the 
antibody, eluting the antigen from the antibody, and finally regenerating the stationary 
support for the next isolation.257,258 In the IAC the elution is mainly done with non-
specific elution by altering the binding conditions. Dissociation of the antigen from the 
antibody is promoted by changing the ionic strength, polarity or pH of the mobile 
phase, or antigen mimicking epitope peptide.
Monolithic columns can be utilized for the IAC by immobilizing the antibody on such 
column. The monolithic columns are suitable for the isolation of biomacromolecules 
due to reduced mass transfer resistance of convective mass transport, also the 
binding capacity is not affected by the flow, and there is a possibility for high flow 
rates with low pressure drop compared to packed particles.259–261 The backpressure 
of the monolithic column can be even half of the backpressure generated by a
particle-based column of the same parameters.262
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The Van Deemter equation (2) can be used to describe the separation and 
performance of monolithic column,= + +      (2) 
where is the theoretical plate height, the Eddy diffusion, the diffusion in 
longitudinal direction, the mass transfer resistance coefficient, and the linear 
velocity. In addition, = / , where is the column length and is the theoretical 
plate number. In this equation it can be seen that lower values indicate higher 
efficiency, since a higher theoretical plate number per column length is achieved. Eq.
(2) can be expanded into Eq. (3) to take into account experimental parameters,263= 2λ + + ( ) (3) 
such as the factor for the shape of material packing λ, the particle diameter , the 
obstruction factor , the diffusion coefficient of the analyte in the mobile phase ,
and the retention factor . The following pore size ranges can be classified:
macropore ( > 50 ), mesopore ( = 2 − 50 ), and micropore ( < 2 ).263
A small particle diameter reduces the theoretical plate height significantly according 
to Eq. (3) due to the decreased effect of mass transfer resistance described by term 
in Eq. (2). Thus, increased separation efficiency and reduced separation time can 
be achieved by reducing the particle size in the particle-based columns, but the 
smaller the particles get, the higher the pressure drop develops. This is not a wanted 
feature for separating biomacromolecules, shifting the usable particle diameters to 
mesopores and macropores.262,263 In addition, the monoliths do not contain areas 
accessible only by slow diffusion that are found in stagnant fluid in the pores of the 
particles in the particle-based columns. Thus, interactive sites at the monolithic 
surfaces are easily accessible for the biomacromolecules by convective flow, further
reducing the mass transfer effect.264 The convective flow allows laminar flow that 
minimizes the shear forces.265 High porosity of the monolithic columns allows the low 
pressure drop described by Darcy’s law, and consequently high flow rates,266= μ   (4) 
where is the flow velocity, μ the dynamic viscosity of the fluid, the column length, 
 the hydraulic permeability, and the pressure drop difference across the 
monolithic column. A broader range of properties of the monolithic columns can be 
described by the Happel equation,262,266
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= ( )/  (5)
where γ = (1 − ɛ ) and ɛ is the porosity in the monolithic column.
3.2 Asymmetrical flow field-flow fractionation 
In AsFlFFF or AF4 only one side of the wall (accumulation wall) of the separation 
channel is permeable to the flow (Figure 7). The channel inlet is divided into main 
flow and cross flow that is perpendicular to the main flow. Three mechanisms are 
possible for retention in the AsFlFFF: hyperlayer, steric, and normal modes. The 
channel shape can be trapezoidal or rectangular. AsFlFFF utilizes opposing flow 
relaxation to let the biomacromolecules equilibrate, since the flow cannot be stopped 
independently of the field as in symmetrical FFF. The sample in AsFlFFF is injected 
from a separate inlet that comes just after the flow inlet. The sample can, however,
be injected from any point between the inlet and outlet and be dispersed widely across 
the channel, since the carrier liquids from both inlet and outlet are collected into a
focusing point before the relaxation.120 This creates a narrow zone of the sample in 
the focusing point. The focusing position can be shifted by changing the opposing 
flow rates:=   (6)
where ′ is the focusing point from the channel inlet, is the inlet flow rate, 
is the outlet flow rate, and Lchannel is the length of the channel.
Retention time ( ) in the normal mode depends on the hydration size of the 
biomacromolecules,267=   (7)
where η is the dynamic viscosity of the carrier liquid, w is the channel thickness, is 
the hydration diameter of the biomacromolecule, is the cross-flow rate, is the 
Boltzmann constant, is the temperature, and is the axial flow rate.
In AsFlFFF only one pump is needed due to only one permeable membrane. Loss of 
liquid through a membrane generates the cross flow. The trapezoidal channel with 
decreasing width is designed to compensate the liquid loss generated due to the loss 
of carrier liquid through the membrane while moving down the channel and to keep 





Figure 7. Separation of biomacromolecules in normal mode in the AsFlFFF channel. 
Adapted from Postnova Analytics. 
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3.3  Capillary electrophoresis 
 
In capillary electrophoresis (CE), charged biomacromolecules are separated in 
electrolyte solution (BGE) under a high electric field based on their molecular structure, 
size, and charge (Figure 8). Fused silica capillaries of diameter 25-100 μm and length 
of  25-100 cm are used.127–129  
 
 
Figure 8. Schematic illustration of capillary electrophoresis instrumentation.  
 
Deprotonation of silanol groups of the fused silica capillary begins above pH 2. A 
double layer and a potential difference between the capillary wall and the bulk liquid  
are generated by the interaction of the positive ions of the BGE with the capillary wall. 
The positively charged diffuse layer advances toward the cathode generating 
electroosmotic flow (EOF) when voltage is applied. EOF can be exploited in the 
separation of small molecules but due to the adsorption of proteins to uncoated silica 
capillary, it is often an unwanted phenomenon during bioseparations. The modification 
of silanol groups can be done covalently or by charged and neutral surface coating. 
This allows controlling or even eliminating the EOF by diminishing the surface 
adsorption. Neutral coatings have been successfully applied to the biological analysis 





The total mobility of a charged biomacromolecule (μ tot) is a sum of the electroosmotic 
mobility in the fused silica capillary (μ eo) and the electrophoretic mobility of the 
biomacromolecule (μ ep), and can be experimentally determined from the migration 
time of the biomacromolecule (t m) according to the following equation:  μ = μ + μ =       (8) 
where  is the total capillary length,   is the length to detector, and  is the 
voltage utilized in the separation. 
Partial filling affinity capillary electrophoresis (PF-ACE) is possible when receptor and 
analyte have large enough differences in the mobilities so that the receptor can 
migrate through the analyte zone268 (Figure 9). 
 
 
Figure 9. Schematic illustration of the PF-ACE method on a coated silica capillary.  
 
The PF-ACE method can be utilized to determine the affinity constant (Ka) of the 
formed complex.155 If the field strength and conductivity stay uniform in the capillary, 
the affinity constant can be determined:  
 = = , ∆       (9) 
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where is the dissociation constant, is the inner radius of the capillary, , is the 
time that the analyte needs to reach the detector when the receptor is not present, ∆ is the changes in the migration times, is the molar amount of the receptor.
3.4 Continuous flow quartz crystal microbalance
Developed in 1957 by G. Sauerbrey,269 QCM is a mass sensitive technique that
utilizes voltage generated by piezoelectric effect of quartz crystal during mechanical 
stress. The change in frequency upon mass deposition on the surface of the quartz 
crystal is described by the Sauerbrey equation,270∆ =  − ·  ∆ (10)
where ∆ is the change in mass on the surface of the quartz crystal, ∆ is the 
frequency change of the oscillating crystal, and is the mass sensitivity constant.
According to the equation, the frequency shifts are correlated with changes in the
mass on the surface of the crystal. Higher sensitivity can be achieved by cutting the 
crystal thin, and immobilization of ligands is enabled by coating the crystal surface
with gold.271–273 The basic principle of QCM to study interactions between antibody 
and biomacromolecules is depicted in Figure 10. After the equilibration, the oscillator 
undergoes an association of the biomacromolecules resulting in frequency shift
followed by a dissociation phase where the interaction is broken. Finally, regeneration 
of the oscillator returns the frequency back to the base frequency. Collected 
sensogram at different analyte concentrations can be further analyzed with global 
fitting algorithms, adsorption energy distribution (AED) calculations,135 rate constant 
distribution maps (RCD), as is done in this thesis, or even with a more advanced data 










This chapter collects the lists of antibodies (Table 2), chemicals (Table 3), and 
materials, instruments, and equipment (Table 4) used in the studies. Detailed 
information is found in Papers I-IV. Figures in the thesis were created with 
BioRender.com.
Table 2. List of antibodies 
Antibody Supplier Paper
Purified Mouse Anti-Human CD61 
(clone VI-PL2) antibody
BD Biosciences II-IV
Purified Mouse Anti-TSG101 
Clone  51/TSG101
BD Biosciences II
CD9 Monoclonal Antibody (eBioSN4 
(SN4 C3-3A2)), eBioscience™
Thermo Fisher Scientific III-IV
Mouse Monoclonal Anti-CD9 Antibody 
(C-4): sc-13118
Santa Cruz Biotechnology II
Human monoclonal anti-human-




HRP-conjugated sheep anti-mouse IgG 
antibody
GE Healthcare II
















Acetic acid VWR III
Acetonitrile
(gradient grade, purity ≥99.9%)
Sigma-Aldrich IV
Ammonia 25% (NH3) Riedel-de Haën I-IV
BCA Protein Assay Kit Thermo Fisher Scientific IV
Bovine Serum Albumin (BSA) Sigma-Aldrich I-II
Bovine milk Excilone III
Buffer solutions: pH 4 (phthalate), pH 7 
(phosphate), and pH 10 (borate)
Fisher Scientific I
Cholesterol CHOD-PAP reagent Roche IV
Clarity ECL substrate Bio-Rad II
DC Protein assay Bio-Rad II, IV





Ethylenediaminetetraacetic acid disodium 
salt dihydrate (Na2EDTA)
Sigma Chemicals I
Gentamycin sulfate Lonza I
Glycine Sigma-Aldrich II
Formic acid VWR Chemicals IV
HDL2 Wihuri Institute I
Human plasma




Hydrochloric acid (0.1-1.0 M) FF-Chemical Ab I-IV
Hydrochloric acid (fuming 37%) Fluka / Sigma Aldrich I-II
IDL-VLDL Wihuri Institute I
LDL Wihuri Institute I
Methanol (99%) Honeywell IV
N-Hydroxysulfosuccinimide sodium salt 
(sulfo-NHS)
Aladdin Chemical Reagent 
Company
I
ortho-Phosphoric acid Merck KGaA I
PageRuler prestain protein ladder Thermo Fisher Scientific II
Phosphate buffered saline (PBS) tablets Sigma-Aldrich II-IV




Pony plasma Excilone III
Pony serum Excilone III
Sodium acetate Sigma-Aldrich III
Sodium azide (NaN3) Sigma-Aldrich I





Sodium chloride (NaCl) Fisher Chemicals I
Sodium citrate trihydrate (C6H5O7·3Na·3H2O) Sigma-Aldrich I
Sodium dodecyl sulfate (SDS) Sigma-Aldrich III
SDS-PAGE (12%) Thermo Fisher Scientific II









Tris(hydroxymethyl)aminomethane (Tris) Sigma-Aldrich III
TWEEN® 20 Sigma-Aldrich I
Vybrant™ CFDA SE Cell Tracer Kit (dye 5-
(and-6)-Carboxyfluorescein diacetate 
succinimidyl ester, CFDA-SE)
Thermo Fisher Scientific III
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Table 4. Materials, instruments, and equipment
Materials, instruments, and 
equipment
Manufacturer Paper
14 position stream selection valve 
(Cheminert C25Z-31814D)
Vici AG IV
AF2000 AsFlFFF system Postnova Analytics II-IV
AF2000 program Postnova Analytics II-IV
AF2000 MT series membrane 
(10 kDa mass cut-off regenerated 
cellulose)
Postnova Analytics II-IV
AF2000 MF spacer (350 μm) Postnova Analytics II-IV
Agilent CE ChemStation Agilent I
Agilent 3DCE instrument Agilent I
CBM-20A modular system 
controller
Shimadzu III-IV
Centrifuge (Allegra X-15R) Beckman Coulter III
Centrifugal filter units 
Amicon 100 kDa
Nanosep Omega Membranes 3K







CIM® CDI -0.34 mL disk BIA Separations II-IV
Diode array detector (DAD) 
(G1315A)
Agilent Technologies IV
Disk housing BIA Separations II-IV
Dynamic light scattering (DLS)
instrument (Zetasizer Nano)
Malvern Instruments II-IV
Exosome Spin Columns (MW 3000) Thermo Fisher Scientific III
Filters
Supor®-200 membrane filters, 0.2
μm
MILLEX® Low Protein Binding 






Fraction collector (FRC-10A) Shimadzu III-IV
Freeze dryer (Heto PowerDry 
LL1500)
Thermo Scientific III





HPLC system (Agilent 1260
Infinity)
Agilent IV
Isocratic high-performance liquid 









Microplate reader (Multiscan EX) Labsystems Diagnostics II
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Materials, instruments, and 
equipment
Manufacturer Paper
Millipore water purification system





Model E60 actuator Vici AG IV
Multiangle laser light scattering (MALS) 
detector (Postnova PN3070)
Postnova Analytics II-IV
Nanoparticle Tracking Analysis (NTA)
Zetaview
Nanosight NS300 instrument








Quartz crystal microbalance (QCM) 
(Attana A100)
Attana AB I
PA 800 Plus system Sciex Separation III






Plate reader (EnSpire 2300) PerkinElmer Inc IV
Polyvinyl Alcohol (PVA) neutral 
capillaries
Sciex III
Purging port (PN1610) Postnova Analytics II-IV
Scanning
electron microscope (SEM)
(Hitachi S-4800 field emission SEM)
Hitachi IV
SEC column (qEVoriginal) Izon Science III
SeQuant® ZIC®-cHILIC column
(150 mm x 2.1 mm i.d., pore size 100 
Å,3 μm particle size)
Merck KGaA IV
SeQuant® ZIC®-cHILIC guard
column (20 mm x 2.1 mm i.d., 200 Å 
particle size, particle size 5 μm
Merck KGaA IV
Single board computer (Model B Rev. 
2.0)
Raspberry Pi IV
Six-port medium pressure injection valve 
(V-45)
IDEX Upchurch Scientific IV
Solid-state laser induced fluorescence 
detector
Integrated Optics III
Solvent degasser (PN7520) Postnova Analytics II-IV
Solvent organizer (PIN PN7140) Postnova Analytics II-IV
Sputter coater (208HR) Cressington IV
Syringe pump (Sp100i) WPI II-III
Syringe pump (Kloehn v6) Postnova Analytics II-IV






UV detector (SPD-20A Prominence) Shimadzu II-IV










Vacuum-driven fi ltration system 
(Millipore Steritop, 0.22 μm)
Millipore III
Water bath MGW (Lauda K2) Lauda-Köningshofen I






4.1.1 Preparation of buffers and solutions
Phosphate buffer and phosphate buffered saline (PBS) (Papers I-IV)
The phosphate buffer (I = 20 mM) used in the CE and QCM experiments was 
prepared by adding 485 μL of phosphoric acid (85%) and dissolving it with 14.16 ml 
of 1.0 M NaOH to 900 ml of Milli-Q water. The pH of the solution was first adjusted to 
7.4 with 1.0 M HCl and then filled to the final volume of 1000 ml with Milli-Q water. To 
calculate the ionic strength of the buffer, pKa,2 of 7.2 was used for phosphoric acid.277
(Paper I)
For the isolation and fractionation of the biomacromolecules, phosphate-buffered 
saline (PBS, pH 7.4) was also utilized. It was prepared following the standard 
procedure, either from 10x PBS solution or PBS tablets. One PBS tablet was 
dissolved into 200 mL Milli-Q water and filtered through a 0.2 μm membrane filter.
(Papers I-IV)
Ethanolamine (Papers II-IV)
1 M ethanolamine solution (pH 9.0) was prepared by adjusting the pH with 
hydrochloric acid (fuming 37%). (Paper I) 2 M ethanolamine, pH 9.0, was prepared 
by adding 0.603 mL of ethanolamine in a small amount of Milli-Q water and then 
900 μL of fuming 37% HCl was added by placing the pipette tip directly inside the 
ethanolamine solution. The final solution was prepared by topping up the total volume 
to 5 mL with Milli-Q water. 
Ammonium hydroxide (NH4OH) (Papers I-IV)
The ammonium hydroxide solution (NH4OH), pH 11.3, was prepared by adding 
2.26 mL of 25% ammonia and filling it to a final volume of 100 mL with Milli-Q water.
Carbonate-bicarbonate solution (Papers II-IV)
1.06 g of anhydrous Na2CO3 was dissolved in 100 mL Milli-Q water to prepare 0.1 M 
Na2CO3 stock solution. 0.8401 g of NaHCO3 was dissolved in 100 mL Milli-Q water to 
prepare 0.1 M NaHCO3 stock solution. The carbonate-bicarbonate solution was 
prepared by mixing 90 mL of 0.1 M Na2CO3 stock solution with 10 mL of 0.1 M 
NaHCO3 stock solution. The pH of the solution was adjusted to 11.3 with NaOH. 
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CE-LIF background electrolyte solution (Paper III)
The capillary electrophoresis - laser-induced fluorescence (CE-LIF) background 
electrolyte (BGE) was prepared from two stock solutions of 1.5 M Tris and 1.2 M 
CHES. 1.5 M Tris was prepared by dissolving 1.817 g of Tris base in 10 mL of water 
and 1.2 M CHES by dissolving 10.447 g of CHES in 42 mL of water. Then, 8 mL of 
1.5 M Tris was mixed with 41.09 mL of 1.2 M CHES. Deionized water was then added 
to a total volume of 50 mL. 
Solutions for QCM studies (Paper I)
A phosphate buffer (I = 20 mM) was used to dilute anti-apoB-100 mAb (100 μg/mL)
before using the antibody for amine coupling on the surface of LNB-Carboxyl chip.
The buffer (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4) utilized for the 
immobilization was prepared by dissolving 1.19 g of HEPES with 4.38 g of NaCl and 
0.25 ml of 10% Tween 20 in 400 ml of Milli-Q water, followed by adjustment to pH 7.4 
with 1.0 M NaOH. The final volume of the immobilization buffer was adjusted to 500 
mL with Milli-Q water. The activation reagents, 0.4 M EDC and 0.1 M S-NHS, were 
both dissolved in Milli-Q water before mixing. The LDL and IDL-VLDL samples (3–
110 μg/mL) used in the QCM experiments were diluted in the phosphate buffer (I =
20 mM). A regeneration solution was prepared by diluting 25% ammonia in Milli-Q
water to obtain 0.28 M ammonium hydroxide pH 11.5. The immobilization solution of 
anti-apoB-100 mAb was prepared in the same manner as mentioned above using the
phosphate, but the pH was adjusted to 6.4 with 1.0 M HCl. 
HILIC-MS/MS mobile phase (Paper IV)
The HILIC-MS/MS mobile phase A was prepared by adding 1 mL of formic acid to 
acetonitrile (999 mL) and the mobile phase B was prepared by adding 1 mL of formic 
acid to MQ water (999 mL). All standards and internal standards were prepared in 
mobile phase B. 
4.1.2 Immobilization procedures
Immobilization of anti-apoB-100 mAb on LNB-Carboxyl sensor chip
(Paper I)
Immobilization of anti-apoB-100 mAb was done with an amine coupling procedure 
according to the manufacturer's recommendations with slight modifications. Prior to 
the immobilization the LNB-Carboxyl sensor chip was pre-wetted ex-situ with 20 μL
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of Milli-Q water and thereafter inserted into the instrument and left to stabilize. The 
immobilization was performed with the analysis buffer (10 mM HEPES, 150 mM NaCl, 
0.005% Tween 20, pH 7.4) at the flow rate of 10 μL/min at 25°C. To activate the 
surface, freshly mixed 0.4 M EDC and 0.1 M S-NHS (1:1, v/v) was injected using 
automated C-Fast software for 5 min. The surface activation was done once. The 
amine coupling of anti-apoB-100 mAb (100 μg/mL in phosphate buffer; pH 6.4) was 
carried out by injecting the solution twice for 5 min. Finally, the remaining carboxyl 
groups were deactivated with two injections (5 min each) of 1 M ethanolamine solution 
(pH 9.0).  
Immobilization of antibodies on CIM® CDI - 0.34 mL disk (Papers II-IV) 
A CIM® CDI -0.34 mL disk, with the pore size of 1.3 μm, was placed in the disk housing 
and washed with 6.8 mL of Milli-Q water followed by 15 mL of PBS buffer (pH 7.4). 
The antibody (1 mL of 0.5 mg/mL of anti-CD9 (Papers III-IV), anti-CD61 (Papers II-
IV), and 5 mL of 0.5 mg/mL of anti-apoB-100 (Paper IV)) was injected through the 
housing back and forth using a syringe pump and two syringes at both ends of the 
column with a flow rate of 0.5 mL/min for 1.5 h at room temperature. The cycle of 
injecting back and forth was repeated five times daily for three consecutive days. The 
disk was left over a weekend to ensure maximum antibody immobilization, the disk 
was then washed with 3 mL of PBS, and the remaining CDI groups were deactivated 
by passing 1 mL of 2 M ethanolamine (pH 9.0) through the system twice and left 
overnight with stoppers. The immobilization procedure is depicted in Figure 11. The 
system was finally washed with 20 mL PBS buffer to remove the excess 
ethanolamine.  
 




4.1.3 Isolation of biomacromolecules
Isolation of high-density lipoprotein (HDL2) with ultracentrifugation
(Paper I)
HDL2 was isolated from serum and plasma samples by sequential ultracentrifugation 
and KBr was used for density adjustment. After the first isolation of apoB-100
containing lipoproteins at d = 1.063 g/mL (5 °C, 3 h, 500,000 × g), the infranatant 
fraction was adjusted to density 1.125 g/mL with solid KBr and then centrif uged (5 °C, 
18 h, 500,000 × g). The HDL2 was obtained in top fraction. The purity of the isolated 
HDL2 was checked with FPLC size-exclusion chromatography. The isolated HDL2
was dialyzed against phosphate-buffered saline (PBS, pH 7.4) and stored at −80 °C 
before analysis. 
Isolation and characterization of apoB-100 containing lipoproteins (LDL, 
IDL-VLDL) with ultracentrifugation (Papers I and IV)
Human LDL (d = 1.019–1.050 g/mL) was isolated by sequential ultracentrifugation in 
the presence of 3 mmol/L Na2EDTA.278,279 First, EDTA and 100 μg/mL gentamycin 
sulfate were added to the plasma sample and the density was adjusted to 1.019 with 
KBr. Then, the plasma sample was centrifuged at 40,000 rpm (rotor 50.2 Ti, gmax
302,000) at +4 °C for 24 h. The IDL-VLDL fraction was collected from the top and the 
density of the remaining plasma was set to 1.050 g/mL with KBr. The density-adjusted 
plasma was centrifuged at 40,000 rpm for 72 h and the plasma for further steps was 
collected on the top of the solution. The collected solution was re-centrifuged at a 
density of 1.063 g/mL for 24 h, collected and dialyzed extensively against 150 mM 
NaCl – 1 mM EDTA (pH 7.4) followed by dialysis against phosphate-buffered saline 
(PBS, pH 7.4). 
Isolation of bovine milk-derived EVs with sucrose gradient 
ultracentrifugation (Paper III)
Whole bovine milk samples were centrifuged at 3,000×g for 30 min at 4 °C (Allegra 
X-15R, Beckman Coulter) to separate fat from skimmed milk. The whey was obtained 
after acid precipitation of milk (50 mL) with 5 mL of 10% acetic acid and incubation at 
37 °C for 10 min. This was then continued by addition of 5 mL of 1 M sodium acetate, 
and incubation for 10 min at room temperature, followed by centrifugation at 1,500×g, 
4 °C for 15 min and filtration of supernatant using vacuum-driven filtration system 
(Millipore Steritop, 0.22 μm). The whey supernatants were concentrated by the 
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centrifugation at 4,000×g and 20 °C using Amicon 100 kDa centrifugal filter units. The 
obtained retentate was ultracentrifuged for pelleting the EVs at 100,000×g for 1h 10
min at 4 °C (Beckman Coulter, Optima XPN-80, 50TI rotor). The pellets were 
solubilized in 500 μL of PBS then added to 11 mL of pre-prepared sucrose gradient 
5–40% and ultracentrifuged at 200,000×g for 18 h at 4 °C (SW41 rotor). Selected 
fractions corresponding to flotation densities of EVs’ (1 mL) were collected, diluted in 
6 mL of PBS and finally centrifuged at 100,000×g for 1h 10 min at 4 °C (50TI rotor). 
The pellets were re-suspended in 50 μL of PBS and stored at −80 °C.
Isolation of pony plasma/serum and human plasma derived EVs with
size-exclusion chromatography (Paper III)
Preparation of plasma: Peripheral blood was collected into EDTA-coated vacutainer 
tubes. After ten-time inversion, the samples were processed within 60 min of 
collection. Consecutive centrifugation steps at 2,500×g, 4 °C for 15 min and then at 
15,000×g for 10 min were performed followed by filtration of the supernatant through 
0.22 μm filters. 
Preparation of serum: Whole blood was collected into anticoagulant-free tubes and 
allowed to clot at room temperature for 45 min. The clot was removed by centrifuging 
at 3,200×g, 4 °C for 15 min, followed by centrifugation at 15,000×g, 4 °C for 10 min 
and filtration of the supernatant through 0.22 μm filters.
500 μL of pre-treated plasma/serum was loaded onto a qEVoriginal SEC column (Izon 
Science) that was washed and equilibrated with PBS. Fraction collection (0.5 mL per 
fraction) was carried out immediately using PBS as elution buffer. The selected 
elution fractions were pooled and were subsequently concentrated using 100 kDa 
Amicon centrifugal filter units. Post-treatment processing with several washing steps 
with PBS was applied to obtain highly pure EV fractions. 
Isolation of human plasma-derived EVs with monolithic immunoaffinity 
chromatography (Papers II-III)
Monolithic disk columns were injected with diluted human plasma samples (250 μL 
of plasma diluted to 5 mL in PBS) immobilized with either anti -human CD61 or anti-
human CD9 antibodies. Unbound plasma was washed away with 3 mL of PBS. The 
enriched EVs were eluted with 2 mL of either ammonium hydroxide (NH4OH, pH 11.3) 
or carbonate-bicarbonate (pH 11.3) solution. The pH of the isolates (final volume 0.5 
49 
 
mL) was adjusted by addition of 50 μL of 1 M HCl. The monolithic disk columns were 
equilibrated with 3 mL of PBS before the next sample injection.
Isolation of human apoB-100 containing lipoproteins, CD9+, and CD61+
EVs by the on-line immunoaffinity chromatography - asymmetrical flow 
field-flow fractionation system (Paper IV)
Three separate monolithic disk columns for the IAC were immobilized with anti-apoB-
100, anti-CD9, and anti-CD61. The IAC process cycles (Figure 12) for the isolation of 
apoB-100 containing lipoproteins, CD9+, and CD61+ EVs can be found in Table 5.
The repetition of the successive experiments is shown in Figure 12 where the 
regeneration and waiting periods were taken into account for the AsFlFFF to be ready 
for the next fractionation. The total time for apoB-100 lipoprotein isolation and 
regeneration of the disk column was 16.5 min (1 mL sample injection, 3 mL PBS 
wash, elution with 2 mL of NH4OH, and 3 mL PBS wash). The isolation and 
regeneration cycle for the EV disks took 51 min. The major difference between the 
isolations was that EV isolations had a larger sample volume (5 mL) and an additional 
NH4OH regeneration step. The carbonate-bicarbonate solution was used to elute the 
EVs. The flow rate for the apoB-100 containing lipoprotein isolation and elution was 
set to 0.5 mL/min, whereas it was 0.25 mL/min for the EV isolation. The regeneration 
step for EV disks before the analysis of the next sample was performed with 2 mL of 
NH4OH and 3 mL of PBS at a flow rate of 1 mL/min. No additional regeneration step 
was needed for the apoB-100 disk, since NH4OH was already used for the elution. 
The AsFlFFF run was automatically started after the eluent of the IAC filled the 
sample loop (500 μL) after the void volume in the six port valve. 
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Figure 12. Repeated successive IAC-AsFlFFF analysis cycles. A short cycle was 
used for isolation and fractionation of apoB-100 containing lipoproteins and long cycle 
for EVs. An automated injection to the AsFlFFF was done when eluate from IAC was 
fully transferred to the sample loop of the six port valve. 
 
Table 5. Process cycles used in the IAC. 
Isolation program for apoB-100 
containing lipoproteins 
 
EV isolation program 
 
  mL mL/min min   mL mL/min min 
Sample 
loading 1 6 0.167 
Sample 
loading 5 6 0.833 
Sample 
injection 1 0.5 2 
Sample 
injection 5 0.25 20 
PBS loading 3 6 0.5 PBS loading 3 6 0.5 
PBS 
injection 3 0.5 6 
PBS 
















2 0.25 8 
PBS loading 3 6 0.5 PBS loading 3 6 0.5 
PBS 
injection 3 1 3 
PBS 
injection 3 1 3 




2 6 0.333 




2 1 2 
     PBS final 
loading 3 6 0.5 
     PBS final 
injection 3 1 3 
       total  51 
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4.1.4 Fractionation of biomacromolecules
The collected EVs (500 μL) from anti-CD61 or anti-CD9 disk were manually injected 
to the AsFlFFF (Papers II-III), while the on-line system was utilized for automatic 
injection of the lipoprotein and EV samples (Paper IV). Optimal conditions for all of 
the AsFlFFF experiments are listed in Table 6. (Papers II-IV)
For labeling, the EV fractions (300 μL each) obtained with AsFlFFF were frozen and 
subsequently lyophilized over 3 h at a temperature of −110 °C. Before starting the 
labeling protocol, the fractions were rehydrated with 30 μL PBS for EVs enrichment. 
(Paper III)
Table 6. Optimal AsFlFFF conditions for fractionation of apoB-100 containing 
lipoproteins and EVs.



































































Separation Time 5 min 2 min 2 min 5 min















Time 15 min 1 min 1 min 15 min












Time 10 min 15 min 15 min 14 min
Cross-flow 0 mL/min 0 mL/min 0 mL/min 0 mL/min
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4.1.5 Capillary electrophoresis of biomacromolecules
Capillary electrophoresis coating procedure (Paper I)
Unfavorable adsorption of lipoproteins on the negatively charged fused-silica capillary 
was diminished by coating the capillary inner wall with quaternized double-hydrophilic 
poly(N-methyl-2-vinyl pyridinium iodide-block-ethylene oxide) (P2QVP-b-PEO) 
diblock copolymer.280 P2QVP-b-PEO was dissolved in Milli-Q water to a concentration 
of 0.1 mg/mL. The coating procedure was slightly modified from previous 
studies.142,280 First, an uncoated fused-silica capillary was pretreated by flushing for
15 min, 10 min, and 10 min with 0.1 M NaOH, Milli-Q water, and phosphate buffer 
(pH 7.4, I = 20 mM) at a pressure of 940 mbar. Then the capillary was flushed for 20 
min, 10 min, 25 min, and 5 min with 1 M HCl, 0.1 M HCl, Milli-Q water, and the pH 
7.4 phosphate buffer, respectively, at a pressure of 940 mbar. After pretreatment, the 
voltage of +15 kV was applied for 5 min. The P2QVP-b-PEO coating solution was 
then applied for 40 min and left for 30 min to react with the silanol groups on the 
capillary surface. Excess copolymer solution was then rinsed by flushing through the 
capillary for 60 min at a pressure of 940 mbar. The coating procedure with the polymer 
solution was repeated twice to ensure the best possible stability of the wall coating. 
The whole procedure was conducted at 37.0 °C. To ensure the success of the 
coating, EOF mobility was measured using DMSO with the Williams and Vigh 
method.281 The stability of the mobility value was also controlled during the kinetic 
studies. It was at the level of 10-9 – 10-10 m2V-1s-1.
Partial filling affinity capillary electrophoresis (Paper I)
The partial filling (PF) procedure in the CE was modified from our previous 
studies.135,137,139,142,159 Briefly, negatively charged analytes were hydrodynamically 
introduced to the P2QVP-b-PEO coated capillary. First, slightly negative anti-apoB-
100 mAb was introduced in the concentration range of 0.0002 to 0.1 mg/mL for 3 s, 
followed by injection of the more negative lipoproteins at 50 mbar pressure.280 Fused-
silica capillaries (i.d. 50 μm) had a length of Ltot 38.5 cm and Ldet 30 cm. The lipoprotein 
concentrations were different for the antibody-antigen studies. The LDL (0.075 
mg/mL) was introduced for 2 s, the IDL-VLDL (0.0036 mg/mL) for 8 s, and the HDL2
(0.20 mg/mL) for 2 s at 50 mbar. When the voltage of -25 kV was applied and detector 
was in the cathode end, more anionic lipoproteins reached anti-apoB-100 mAb and 
formed the LDL -, IDL -, and VLDL - anti-apoB-100 mAb complexes. HDL2 lacking 
apoB-100, was used as a control to test the specificity of the anti-apoB-100 mAb. The 
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detection was performed at the wavelength 200 nm. Before each run, the capillary 
was rinsed for 2 min with the phosphate buffer (pH 7.4). All the experiments were 
conducted at 37.0 °C. After every second run, the EOF mobility was measured to 
control the stability of the coating.
Fluorescent labeling of EVs (Paper III)
The fluorescently labeled EVs were prepared using the 5-(and-6)-carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE). The CFDA-SE stock solution (10 mM) was 
prepared in DMSO following the manufacturer’s instructions. Prior to the staining, the 
working solution was diluted to 200 μM in PBS. 20 μL of EVs was mixed with 20 μL 
of 200 μM CFDA-SE solution (resulting in a final CFDA-SE concentration of 100 μM), 
and incubated for 2 h in the dark at 37 °C with gentle shaking. 
Removal of free label (Paper III)
Labeled EVs were obtained from two different matrix exchange approaches, using 
either centrifugal filtration Nanosep Omega Membranes 3K or with commercial 
Exosome Spin Columns (MW 3,000 Da). The first approach (centrifugal filtration) was 
carried out by addition of the desired buffer to be substituted on the top of the labeled 
EVs, then centrifugal spinning of the column for approximately 4 min at 5,000×g. This 
process was repeated four times. In the last step, a buffer volume equivalent to that 
of labeled EVs was used to maintain the same concentration before and after 
filtration. The Exosome Spin Column approach was carried out according to the 
manufacturer’s instructions. 
CE-LIF of fluorescently labeled EVs and EOF measurement (Paper III)
The fused silica capillary (I.D. of 50 μm, O.D. of 375 μm, effective length (Leff) of 50.2 
cm and total length (Ltot) of 60.2 cm) was pre-conditioned (using a pressure of 172 
kPa at the capillary inlet) with the following sequence: water for 10 min, 1 M NaOH 
for 10 min, 1 M HCl for 10 min and then water for 10 min. The rinsing between two 
analyses was carried out with 50 mM SDS for 5 min, 1 M NaOH for 5 min, deionized 
water for 5 min, and finally the running BGE for 5 min using a pressure of 207 kPa. A 
plug of sample was hydrodynamically injected from the inlet end by applying a 
pressure of 3.4 kPa for 2 min. The separation was carried out under 25 kV (normal 
polarity) at 25 °C and the samples were maintained at 5 °C with the sample storage 
module of the PA 800 Plus equipment. The optimized BGE was composed of 
Tris/CHES (I = 90 mM, pH 8.4). 
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The calibration curve was acquired using bovine milk derived EV standards. The EV
isolates were diluted with PBS to prepare different initial EV concentrations from 1.65 
× 1010 to 1.65 × 1011 EVs/mL before the labeling and matrix removal on spin columns. 
20 μL of EVs was mixed with 20 μL of CFDA-SE 200 μM solution (resulting in a final 
CFDA-SE concentration of 100 μM CFDA-SE), and incubated for 2 h at 37 °C. Then 
40 μL of labeled EVs was loaded into EV Spin Columns and recovered in Tris/CHES 
90 mM. Calculations for the final concentrations were based on the initial 
concentrations measured by NTA before the labeling and taking into account a 
recovery of 75% from the matrix substitution step. EOF mobility was measured with 
CE-LIF using 4-(4-methoxybenzylamino)-7-nitro-2,1,3-benzoxadiazole (MBD) which 
is a neutral and fluorescent compound.282 The EOF marker was dissolved in a 
DMSO:CH3OH (1:1 v/v) solution to a concentration of 20 mM, and then further diluted 
to 2 mM in BGE before use.
4.1.6 Characterization of biomacromolecules
Amino acids and glucose extraction from EVs (Paper IV)
CD9+ and CD61+ EV fractions (from IAC-AsFlFFF system) were subjected to 
preconcentration and salt removal with disposable Nanosep centrifugal devices with 
10 kDa molecular weight cutoff membrane filters at 14,000 g for 2 min for each 500 
μL fraction at room temperature. The filtrate was discarded. Thereafter, cold 
acetonitrile (50 μL) was added to the membrane for EV lysis and removal of 
precipitated proteins. Cold acetonitrile precipitated proteins effectively from human 
plasma283 and lysed the lipid bilayer membranes.284 After vortexing, the filter unit was 
centrifuged for another 2 min at 14,000 g. The filtrate was then collected, and the 
ISTD mixture which yielded the final concentration of 1 ppm of amino acids (glycine-
2,2-d2, l-phenylalanine-3,3-d2, and l-lysine-4,4,5,5-d4) and 5 ppm of d-fructose-13C6 in 
Milli-Q water containing 0.1% formic acid was added to the filtrate for HILIC-MS/MS 
analysis.
Determination of amino acids and glucose by HILIC-MS/MS (Paper IV)
The method used for the determination of amino acids and glucose was based on our 
previously developed method285 with some modifications. The column temperature 
was set to 50 °C. Mobile phase A was acetonitrile with 0.1% formic acid, and mobile 
phase B was Milli-Q water with 0.1% formic acid. The separation of the target analytes 
was performed using the following gradient program: 20% B for 15 min (0.4 mL/min), 
20–80% B for 5 min (0.3 mL/min), followed by 80–20% B for 3 min (0.3 mL/min). The 
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injection volume was 3 μL for all samples. The effluent was electrosprayed, ionized
(positive and negative mode for amino acids and sugars, respectively), and monitored 
by MS2 detection in the multiple reaction monitoring mode (MRM), with the exception 
of glucose, which was analyzed in the single ion monitoring mode.
Nanoparticle tracking analysis (NTA)
Isolated EV samples were analyzed by Nanosight model LM14 equipped with blue 
(404 nm, 70 mW) laser and sCMOS camera. The samples were diluted in PBS and 
three videos of 60 s each were recorded using camera level 14. The data was 
analyzed using NTA software 3.0 with the detection threshold set at 5 and screen 
gain set at 10 to maximize the particles tracking with minimal background. (Paper II)
All experiments were carried out with samples diluted in PBS according to input 
sample concentrations, leading to particle concentrations within the range of 107–109
particles per mL for optimal analysis. The Zetaview system was equipped with a 488 
nm laser. Each experiment was performed in duplicate on 11 different positions within 
the sample cell with the following specifications and analysis parameters: sensitivity 
60, shutter 100, max area 100, min area 5, and min brightness 25. The results were 
validated while obtaining at least 1000 valid tracks for each run. For data capture and 
analysis, the NTA Software version 8.05.04 was used. The particle concentrations
and size distributions were also determined with a Nanosight NS300 instrument 
(Malvern, version NTA 3.2 Dev Build 3.2.16) equipped with a 405 nm laser, sCMOS 
camera type and the NTA software v3.1. The video acquisition was performed using 
a camera level of 14. Per sample, 3 videos of 90 s with a frame rate of 30 frames/s 
were captured at 25 °C and subsequently analyzed with a threshold set up at 5. The 
results were validated with at least 2000 valid tracks for each triplicate. (Paper III)
Protein and cholesterol assays
The amounts of LDL and VLDL-IDL were expressed in terms of the protein 
concentration. The concentrations including that of anti-apoB-100 mAb were 
determined by the method of Lowry et al.,286 DC protein assay, or by the BCA protein 
assay kit based on bicinchoninic assay (BCA)287 using BSA as the standard. Molar 
concentrations of the LDL and the IDL-VLDL were calculated using the molecular 
weight of apoB-100 (512 kDa). For the anti-apoB-100 mAb, molecular weight of 155 
kDa was used. (Papers I-II, IV)
56 
 
Total cholesterol (free and esterified) concentrations in samples were measured 
using the Roche Cholesterol CHOD-PAP reagent according to the manufacturer’s 
protocol. The absorbance was measured with an EnSpire multimode plate reader 
(PerkinElmer) at 510 nm. Calibration curves and sample concentrations were 
calculated using EnSpire multilabel analyzer version 4.13.3005.1482. (Paper IV)
QCM analysis of anti-apoB-100 mAb – lipoprotein interactions (Paper I)
The measurements started after the waiting period of 20 minutes to stabilize the 
resonant frequency in the QCM. LDL and IDL-VLDL samples were injected to the 
surface of chips, monitoring first the association for 50 seconds and then the 
dissociation for 500 seconds. After each association and dissociation cycle, the 
biosensor chip was regenerated with injection of 0.28 M ammonium hydroxide (pH 
11.5) and re-equilibrated with the analysis buffer.
LDL and IDL-VLDL experiments were all carried out at a flow rate of 50 μL / min with 
an injection volume of 35 μL. LDL and anti-apoB-100 mAb interactions were studied 
at temperatures of 25.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, and 40.0 °C. IDL-VLDL 
and anti-apoB-100 mAb interactions were studied at 37.0 °C. LDL and IDL-VLDL 
concentrations ranged from 3 to 110 μg/mL. Three repetitions were made to verify 
the precision of the data. We assumed that the Sauerbrey relation was valid and that 
the QCM frequency shifts are proportional to the adsorbed amount of solute.270
Scanning electron microscopy (SEM) (Paper IV)
Preconcentrated combined fractions of EV subpopulations (produced with IAC-
AsFlFFF) were dried on clean polished silicon wafer surfaces. The samples were then 
coated with a 3 nm Au–Pd alloy using a Cressington 208HR high resolution sputter 
coater and imaged at 3 kV with secondary electrons.
Transmission electron microscopy (TEM) (Paper II)
The EV isolates produced by the IAC were prepared by negative staining as 
described earlier.288 Briefly, EVs were loaded on 200 mesh grids, fixed with 2% PFA, 
stained with 2% neutral uranyl acetate and embedded in a methyl cellulose uranyl 
acetate mixture. 
Western blotting (Paper II)
Proteins from the IAC isolated EVs were separated by 12% SDS-PAGE and 
transferred onto polyvinylidene difluoride (PVDF) membranes. A PageRuler prestain 
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protein ladder of 10–250 kDa was used as the ladder marker. The membranes were 
then probed with antibodies against TSG101 at 1:500 dilution and CD9 at 1:500 
dilution. Proteins of interest were detected with 1:3000 diluted HRP-conjugated sheep 
anti-mouse IgG antibody and visualized with the Clarity ECL substrate according to 
the provided protocol.
4.2 Data analysis
Estimation of kinetic rate constants for QCM (Paper I)
Estimation of kinetic rate constants is an inverse problem, i.e., a problem where given 
the response of the system we want to estimate system parameters. Here we are 
going to estimate system parameter distributions rather than a finite set of system 
parameter values. 
In general, assuming that the total measured response, Rtot, of a system can be 
written as a linear combination of some individual responses r (e.g., Rtot is the sum of 
the responses for all one-to-one interactions for biosensors) we have that
tot 1
; ,n i iiR a Rx p x (11)
where x is the independent variable(s) for the system, e.g. the analysis time, p is the 
system parameter(s), e.g. rate constants, and a is a constant. If we let n in Eq. (11)
→ ∞ we get that,
tot ; ,
mR a R dx p p x p (12)
where Ω m is the considered system parameter space. Eq. (12) is known as an 
Inhomogeneous Fredholm Integral Equation of the first kind with kernel R and our 
goal is to estimate the function a(p). Assume that we have measured the total 
response Rtot(x) for the system, and discretize Eq. (12), the problem of estimating 
a(p) can be written as a linear system of the form
tot( , ) ,M p x a p R x (13)
where M is a matrix and a, Rtot are discrete sample vectors of a(p) and Rtot(x), 
respectively. Eq. (13) is usually an ill-conditioned over- or underdetermined linear 
system and often the condition a ≥ 0 is imposed. In order to get reasonable solutions 
to Eq. (13) regularization is often used, the most common one is Tikhonov 
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where Γ is a regularization matrix (usually an identity or Laplacian matrix) and λ is a 
regularization parameter.
For biosensors the kernel R in Eq. (12) can be written,
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where t (analysis time) and C (analyte concentration) are the independent variables 
and ka, (association rate constant) and kd (disassociation rate constant) are non-
negative system parameters. Above t0 is the time when the injection of the analyte 
begins and tinj is the injection time. The solution a(ka, kd) to Eq. (12) with the kernel in 
Eq. (15) is known as an Interaction Map.289,290 The Interaction Maps in Paper I were 
calculated using the TraceDrawer software from Ridgeview Instruments AB, Sweden.
Determination of affinity constants with PF-ACE (Paper I)
To determine the affinity constants for complexes between LDL, ILD-VLDL and anti-
apoB-100 mAb, the adsorption energy distribution (AED) calculations were used. 
First, the LDL or IDL-VLDL fractions, bound to anti-apoB-100 mAb, were established 
as a function of anti-apoB-100 mAb concentrations. The interactions were studied by 
injecting anti-apoB-100 mAb with increasing concentrations, followed by a constant 
LDL or IDL-VLDL concentration and volume. Then the voltage was applied and LDL 
or IDL-VLDL having more charges than anti-apoB-100 mAb reached the anti-apoB-
100 mAb and interacted with it. 
The average mobility of the antibody-antigen complex can be described with the
following equation,291μ = μ + μ (16)
where Θf and Θb are the free and bound fractions of LDL or IDL-VLDL, respectively, 
and μf and μb are the mobilities of free and bound LDL or IDL-VLDL to anti-apoB-100 
mAb, and μA is the average mobility of the complex. Since Θf + Θb = 1, the equation 
of adsorbed fraction can be presented as:
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= μ μμ μ (17)
Adsorption isotherms and adsorption energy distribution calculations 
(Paper I)
Adsorption isotherms describe the fraction of analyte adsorbed or in free solution at 
equilibrium to a constant and specific temperature.292,293 The Langmuir model that 







where C is the analyte concertation in the running buffer, is fractional surface 
coverage and KA is the association equilibrium constant. As described above the 
Langmuir model can only describe one type of interaction. However, many adsorption 
processes are a result of several different types of interaction such as ion-ion, and 
hydrophobic interactions. One simple way to model a heterogeneous adsorption 
process is to use the bi-Langmuir adsorption isotherm. The bi-Langmuir model is just 
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(19)
Here, indices 1 and 2 denote the first and second adsorption sites, respectively. S,i
is the saturation fraction for the i:th site. Observe that S,1 + S,2 = 1. One other way 
to describe heterogeneous adsorption is to expand the Langmuir adsorption isotherm 
model into a continuous distribution of independent homogeneous sites across a 
















Here, θ(C, KA) is the local adsorption model, and f(ln KA) is the adsorption energy 
distribution (AED). KA,min and KA,max are determined from the inverse maximum and 
minimum sample concentration used in the CE experiments. In Paper I, the AED is 
solved using the expectation maximization method, where the integral equation is 
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iteratively solved.295 Observe that both the AED in Eq. (20) and Interaction Maps are 
both Inhomogeneous Fredholm Integral Equations of the first kind with kernel θ(C,
KA), see Eq. (12). 
Thermodynamics of the interactions (Paper I)
Linear regression analysis of Eq. (21), called van’t Hoff plots can be utilized to 
determine the temperature independent thermodynamic parameters:
lnKD= ΔH/RT-ΔS/R (21)
where KD is the dissociation equilibrium rate constant, R is the gas constant, T is the 
temperature, ΔS is the entropy term, and ΔH is the enthalpy term. The interactions
can be thermodynamically either entropy driven, enthalpy driven, or have equal 
contribution of both.296
Statistical Analysis (Paper IV)
Different R 3.6.3 statistical analysis tools were used in Paper IV. Skewness and 
Kurtosis tests for data distribution evaluation, principal component analysis (PCA) for 
visualization of differences between CD9+ and CD61+ EV subpopulations, and linear 
discriminant analysis (LDA) for statistical confirmation of these differences, including 
clarification of the variables involved in the process. Additional studies were also 
made to evaluate the potential differences between EVs of different sizes (PCA and 
LDA).297
In all of the cases, the concentrations of the free amino acids present in the EVs 
normalized by the total amount of protein were exploited as input variables for the 
development of the statistical models. Additional root square transformation was 
needed to provide normal data distribution of the input variables. 
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5. RESULTS AND DISCUSSION
The major findings of the research and summary of the research results achieved are 
presented in this chapter. For the development of fast, reliable, and automated 
isolation and fractionation methods for nanosized subpopulations of human 
biomacromolecules, first methods to select appropriate ligands were developed 
(Paper I). PF-ACE and QCM were employed to study the antibody-antigen 
interactions between anti-apoB-100 mAb and apoB-100 containing lipoproteins. The 
PF-ACE gave information on the interactions in solution that reached equilibrium, 
while QCM gave information on the kinetics of the interactions of immobilized mAb.
Adsorption energy distribution calculations were exploited to study interaction 
heterogeneity and to determine affinity constants for the PF-ACE data, while 
Interaction maps were for the first time utilized to determine kinetic constants for the 
QCM data. This information is also important in designing isolation systems based on
the IAC, since the antibodies utilized for the isolation of biomacromolecules were
covalently immobilized on the monolithic disks via 1,1'-carbonyldiimidazole (CDI) 
coupling (Papers II-IV).
In addition to the lipoproteins (Papers I and IV), another group of biomacromolecules 
of interest were the EVs (Papers II-IV). The isolation of the EVs is a challenging task 
due to their heterogeneity and overlapping size ranges for the EVs of different sources 
of origin (e.g., co-isolation of ectosomes and endosomes). The matrix of the 
biomacromolecules poses additional challenges, since it is easier to isolate pure 
subpopulations of biomacromolecules from cell culture media or urine compared to 
more complex matrices such as blood plasma or serum. Due to this, the blood 
plasma was selected as the matrix for the IAC (Papers II-IV), inferring that if the 
isolation system works for the more complex matrices, it would be suitable for less 
demanding matrices as well. Further tasks in this thesis regarding the isolation of 
fragile biomacromolecules were: finding biocompatible chromatographic support 
material, finding appropriate elution conditions to disrupt the antibody-antigen 
interactions, and finding a gentle size-based separation technique to complement the 
affinity-based isolation.
The above-mentioned challenges were resolved by utilizing biocompatible convective 
interaction media (CIM) monolithic disk columns as stationary phase in the IAC
(Papers II-IV). The CIM disks had a pore size large enough for the isolation of 
biomacromolecules in the size range of 1-200 nm, fitting the size range for the 
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lipoproteins and the exosome-sized EVs. We also found in Paper I that to disrupt 
strong antibody-antigen interaction and remove the lipoproteins, highly alkaline 
elution conditions (pH above 11.3) were needed. These elution conditions are not 
feasible with silica-based supports unless they are extensively chemically modified to 
stand for higher pH values. The modified silica-based particles for the isolation of 
lipoproteins have also been previously studied in our laboratory298. However, with the
GMA- and EDMA-based polymeric materials utilized in the CIM disks, high pH range 
could be utilized without deteriorating the support material, thus enabling longer life-
time of the isolation system.
Appropriate antibodies were selected to be immobilized on the CIM disks for the 
isolation of EVs and lipoproteins. Anti-CD61 was exploited to target platelet-derived 
EVs (Papers II and IV), while anti-CD9 was used to target EVs that have been 
classically labeled as exosomes (Papers III-IV). Anti-apoB-100 that was 
characterized in Paper I was beneficial for the isolation of apoB-100 containing 
lipoproteins. Further size-based fractionation of EV and lipoprotein subpopulations of 
the IAC isolates were successfully done with AsFlFFF (Papers II-IV). The AsFlFFF 
was coupled with multiple detectors to elucidate the sizes and to allow further studies
of the isolates. NTA, SEM, TEM, and western blot were employed to confirm the 
successful isolation and morphology of the EVs (Paper II). The IAC isolates were also 
studied by CE-LIF and compared to those obtained by other popular isolation 
techniques, such as UC and SEC (Paper III). Subpopulations of EVs were free of
lipoproteins (Papers II-IV) that are usually present after isolation carried out by
conventional isolation techniques and methods. Finally, the IAC and the AsFlFFF 
were integrated into an automated IAC-AsFlFFF on-line system. This automated, on-
line coupled system proved to be fast and give reproducible isolation and fractionation 
of lipoprotein and EV subpopulations with on-line characterization by UV, DLS, DAD, 
and MALS, and fraction collection, allowing further studies to clarify the composition
of free amino acids and sugars in subpopulations of EVs by HILIC-MS/MS (Paper IV).
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5.1 Studies of antibody lipoprotein interactions by partial 
filling affinity capillary electrophoresis and continuous 
quartz crystal microbalance
5.1.1 Lipoprotein and anti-apoB-100 mAb interaction 
studies by partial filling affinity capillary electrophoresis
PF-ACE was utilized to study the interactions of anti-apoB-100 mAb with LDL (Figure 
13A), IDL-VLDL (Figure 13B), and HDL2 (Figure 13C). Based on the 
electropherogram of HDL2 (Figure 13C) the interaction between HDL2 and the anti-
apoB-100 mAb did not result in significant changes in mobility (Figure 13A) since no 
apoB-100 is present in the HDL2 particles, and the interaction was not expected. This 
experiment was used as a control to confirm the selectivity of the anti-apoB-100 mAb.
The selectivity of the anti-apoB-100 mAb towards apoB-100 containing lipoproteins 
could be detected even visually from electropherograms (Figures 13 A and B), since
P2QVP-b-PEO diblock copolymer coating280 suppressed the EOF close to zero at the
level of 10-9 – 10-10 m2V-1s-1. The average mobilities (μA) of the anti-apoB-100 and LDL 
or IDL-VLDL complexes were calculated from electropherograms (Figure 13) after
deducting the EOF. This resulted in noticeable differences between electrophoretic 
mobilities of free (μf) and bound (μb) forms (Figure 14A) that were further investigated 
with exponential and linear fitting. The free LDL or IDL-VLDL were found at the lower
end of the antibody concentration. The maximum value of the electrophoretic 
mobilities of the forms was reached when the LDL or IDL-VLDL were completely 




Figure 13. Partial filling affinity capillary electrophoresis electropherograms as a 
function of concentration of anti-apoB-100 mAb interacting with (A) LDL; (B) IDL-
VLDL; and (C) HDL2. Running conditions: -25 kV, the injection time of LDL 2 sec, IDL-
VLDL 8 sec, and HDL2 2 sec, all at 50 mbar, injection time of anti-apoB-100 mAb was 
3 sec at 50 mbar, 37 °C, Ltot 38.5, Ldet 30 cm, UV detection 200 nm, BGE phosphate 
buffer (pH 7.4, I 20 mM), concentrations of LDL 0.075 mg/mL, IDL-VLDL 0.036 mg/ml, 
and HDL2 0.2 mg/mL, and anti-apoB-100 mAb concentration ranging from 0.00 to 
0.10 mg/mL.  
The electrophoretic mobility data was further utilized to form the adsorption isotherm 
and its corresponding Scatchard plot, and analyzed by AED calculations to provide 
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information on the heterogeneity of the interactions (Figure 14B). The calculations 
revealed that while there were minor differences in the antibody’s binding affinity 
between LDL and IDL-VLDL, the interactions were homogeneous when both the 
lipoproteins and the anti-apoB-100 mAb were free in solution.  
  
Figure 14. (A) The electrophoretic mobilities of the adsorbed and free fractions (B) 
AED calculations for LDL, IDL-VLDL and anti-apoB-100 mAb systems at 37 °C. 
 
The temperature of the system was set to 37 °C to resemble the physiological 
temperature where antibodies bind to lipoproteins in the blood flow. Even though the 
antibody utilized in this study was produced in mouse against human lipoproteins, 
PF-ACE could be used to study e.g., how human antibodies interact with animal 
lipoproteins. Since the aim of this study was to confirm that the strength of the affinity 
of the antibody was high enough for the isolation of human lipoproteins, the PF-ACE 
was a valuable technique to support the use of the anti-apoB-100 mAb (Table 7) in 
the IAC.  
5.1.2 Kinetic and thermodynamic study of lipoprotein and anti-
apoB-100 mAb interactions with quartz crystal microbalance 
and interaction maps 
 
To get still further information about the heterogeneity of the interactions, the 
continuous flow QCM was used. The anti-apoB-100 mAb was immobilized on the 
surface of the QCM chip while in the PF-ACE system the lipoproteins were flowing 
freely in a BGE solution. This was an important set up for the future IAC utilization of 
the anti-apoB-100 mAb, since the anti-apoB-100 mAb would also be immobilized on 
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the monolithic disk columns used for the IAC. It was found that the interactions did 
not reach equilibrium (Figures 15 and 16), but showed high affinity as was already 
shown with the PF-ACE. Thus, a kinetic approach called Interaction Map289,290 
(Figures 15-16 A and B) was utilized for interpreting the sensograms (Figures  15-16 
C and D). The interaction maps were calculated using the TraceDrawer software from 
Ridgeview Instruments AB, and confirmed that the LDL - anti-apoB-100 mAb 
interactions were homogenous with one peak in the interaction map (Figure 15A). 
The affinity constants were calculated from association and dissociation constants 
indicated with intense red color in the Figure 15A and B, and were collected in Table 
7 for different temperatures. The log KA at 37oC was 7.96 with QCM, 7.41 with PF-
ACE, and 7.64 with SPR (obtained as paid services), which shows both the strong 
affinity of the antibody towards the LDL and good reproducibility of affinity constants 
between complementing techniques. 
 
Figure 15. QCM interactions between LDL and anti-apoB-100 mAb at 37 oC 
presented (A) and (B) as interaction maps, (C) as sensograms and model fits for 
association, and (D) as sensograms and model fits for dissociation. The dotted curves 
represent the model fitted sensograms and solid 
curves those obtained from the experimental data.  
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Table 7. Effects of temperature on kinetics and affinity data between anti-apoB-100 
mAb and LDL interactions obtained by QCM using interaction maps, PF-ACE using 











QCM 25 4.68·108 8.67 2.14 8.13·105 1.74·10-3
34 1.45·108 8.16 6.92 7.76·105 5.37·10-3
35 1.23·108 8.09 8.13 7.94·105 6.46·10-3
36 7.24·107 7.86 13.80 6.92·105 9.55·10-3
37 9.02·107 7.96 11.09 8.61·105 9.55·10-3
38 7.41·107 7.87 13.49 9.12·105 1.23·10-2
39 6.03·107 7.78 16.60 8.51·105 1.41·10-2
40 4.57·107 7.66 21.88 8.32·105 1.82·10-2
CE 37 2.54·107 7.41 39.37 ND ND
SPR * 37 4.35·107 7.64 23.00 3.92·105 9.01·10-3
ND, not determined. KA, affinity constant. KD, dissociation constant. ka, association 
rate constant. kd, dissociation rate constant. * data obtained as paid services.
The interaction map for anti-apoB-100 and IDL-VLDL (Figure 16A) shows additional 
peak indicating differences in the kinetics, which could potentially be a result of 
different lipoprotein subpopulations having different association and dissociation 
rates. In addition, since IDL-VLDL is a mixture of heterogeneous lipoprotein classes 
with different sizes and molecular weights, the QCM could also detect the different 
subpopulations due to mass sensitivity. However, more studies would be needed with 
purified IDL and purified VLDL subpopulations to confirm this. The log KA at 37 oC
was 8.00 for the first interaction and 7.80 for the second, while with PF-ACE it was 
7.69 (Table 8). The values were close to those for the interaction between anti-apoB-
100 and LDL. This was to be expected, since the apoB-100 is the protein found in 
both LDL and IDL-VLDL particles and association and dissociation differences might 
be due to size differences of the lipoprotein subpopulations. 
Table 8. Kinetics and affinity data between anti-apoB-100 mAb and IDL-VLDL 
obtained by QCM using Interaction Maps, and by PF-ACE using AED calculations.
ND, not determined. Subscripts 1 and 2, represent sites 1 and 2.  KA, affinity constant. 













































Figure 16. QCM interactions between IDL-VLDL and anti-apoB-100 mAb at 37 oC 
presented (A) and (B) as interaction maps, (C) as sensograms and model fits for 
association, and (D) as sensograms and model fits for dissociation. The dotted curves 
represent the model fitted sensograms and solid curves those obtained from the 
experimental data.   
 
The QCM data at different temperatures for the LDL were plotted as van’t Hoff plot 
(Figure 17) to obtain information on the thermodynamics of the interactions between 
LDL and anti-apoB-100 mAb (Table 9). The interactions were found to be 
predominantly enthalpy driven. 
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Figure 17. Van’t Hoff plot for the interactions between LDL and anti-apoB-100 mAb.
Table 9. The effect of temperature on the derived thermodynamic state functions for 







25 -49.5 -116.7 -225.0
34 -48.0 -116.7 -225.0
35 -47.7 -116.7 -225.0
36 -46.5 -116.7 -225.0
37 -47.2 -116.7 -225.0
38 -46.9 -116.7 -225.0
39 -46.5 -116.7 -225.0
40 -45.9 -116.7 -225.0
Due to the high affinity of the antibody towards both LDL and IDL-VLDL, anti-apoB-
100 was selected as the affinity ligand for the following studies where the antibody 
was immobilized on the monolithic CIM disks and utilized for the isolation of apoB-
100 containing lipoproteins from human plasma. Appropriate elution conditions (pH 
over 11.3) were found for the chip regeneration, which was later applicable also for 
the removal of biomacromolecules from the monolithic disks in the IAC studies.
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5.2  Immunoaffinity chromatography of 
biomacromolecules 
 
In this thesis, the monolithic CIM disks were selected for the isolation of lipoproteins 
and EVs by IAC due to their wide pH stability and large pore size, so that even 
particles that have a diameter of 100 nm could easily pass through the pores. The 
system was first tested in combination with a syringe pump (Figure 18A) and UV-
detector with isocratic sample loading, washing, and elution (Figure 18B). The 




Figure 18. (A) Schematic description of the IAC system and (B) typical isocratic UV-
profile of the IAC sample loading, binding, and elution. 
 
The IAC procedure was the following: load the diluted plasma sample to the monolith, 
wash the non-bound plasma components with PBS, release the biomacromolecules 
with a solution of pH 11.3 (either ammonium hydroxide or carbonate-bicarbonate 
solution), and regenerate the column for the next isolation with PBS. 
The IAC was first used to isolate platelet-derived vesicles with an anti-CD61 disk from 
human plasma at different flow rates (Figure 19A) and the isolated platelet-derived 
EVs were western blotted against common EV markers such as TSG101 and CD9 to 
confirm that the isolated particles were indeed EVs. In addition, the isolates were 
imaged with TEM (Figure 19B) showing typical EV morphology. It can also be noted 




Figure 19. (A) Western blotting and protein concentrations of isolated EVs from 
plasma with the anti-CD61 disk at flow rates 0.25-1.0 mL/min. (B) TEM morphology 
of platelet-derived EVs, isolated with anti-CD61 disk. The isolates show vesicles with 
different diameters and a typical “cup-shaped” EV morphology.
It was found that the protein concentration of the platelet-derived EV isolates 
depended on the flow rates and to maximize the yield 0.25 mL/min should be 
preferred. This can also be noticed in the western blot intensities of the TSG101 and 
the CD9 in Figure 19A. The particle to protein ratio increased a hundred-fold
compared to flow through (Table 10). In addition, the isolates from both plasma and
from platelet-depleted concentrate derived platelet-free plasma had similar mean 
sizes indicating a good size reproducibility between different sample matrices.
Table 10. EV isolation yields from plasma and from platelet-depleted concentrate 
derived platelet-free plasma (PC-PFP). Particle yields and mean sizes were 
determined with the nanoparticle tracking analysis.













Protein yield (μg mL-1) 2637±79 338±72 1147±47 97.7

















5.3 Asymmetrical flow field-flow fractionation of 
extracellular vesicle subpopulations
The isolates were further fractionated utilizing the AsFlFFF due to its many positive 
features such as preserving the integrity of the biomacromolecules, this being of 
importance especially when working with EVs. For example, isolation or fractionation 
with SEC might deteriorate the EVs due to shear forces from the stationary phase.
The platelet-derived EVs (CD61+ EVs) isolated with anti-CD61 disk were manually 
injected to the AsFlFFF (Figure 20) and the subpopulations of the platelet-derived 
EVs with size range <130 nm were detected by UV, MALS (Figure 20A) and DLS 
(Figure 20B) detectors. The size range of isolated platelet-derived EVs corresponded 
to that of exosomes, which was surprising, since the platelets do not have 
multivesicular bodies that would produce exosomes. Thus, it was demonstrated with 
a non-electron microscopy-based method that platelets do indeed secrete exosome-
sized EVs to the circulation. Most importantly, we also detected that the platelets 
secrete EVs of the size of exomeres (<50 nm, 12-17 min) in abundant concentrations 
based on the UV detector signal. Since platelet-derived EVs originate from -
granules7,245,247,248 and not from the multivesicular bodies, - granules might also be 
the source of origin for platelet-derived exomeres. However, more studies are needed 
to define the exact mechanism of the biogenesis.
The shape factor (ρ) of CD61+ EVs was also determined (Table 11) utilizing the size 
data obtained with MALS and DLS detectors. Three different size ranges were 
selected based on the major peak intensities of the flow DLS: <50 nm for exomere-




Figure 20. (A) Normalized AsFlFFF-UV (blue dashed line) and AsFlFFF-MALS (grey 
line) fractograms of isolated CD61+ EVs in PBS, with the root mean square radius of 
gyration, Rg (red circles). The fractionation conditions utilized were: 350 μm spacer, 
cross-flow rate of 3 mL/min, detector flow rate 1.0 mL/min, focusing step 5 min, linear 
decrease in cross-flow to 1.0 mL/min in 5 min, followed by a linear decrease over 15 
min to 0 mL/min. The detector flow was applied for 10 min after the cross-flow was 
off. (B) Raw flow DLS detector signal (blue line) with Z-average or the hydrodynamic 





Table 11. Shape factor (ρ) of CD61+ EVs based on the AsFlFFF fractionation. The 
MALS detector data was utilized for (Dg) and the flow DLS detector data for (Dh). The 
hydrodynamic diameter was obtained with Zetasizer software and root mean square 




<50 nm 60-80 nm 90-120 nm
Dg (nm) 43.4 64.9 100.5
Dh (nm) 45.0 68.5 118.9
ρ= Rg/Rh 0.96 0.95 0.85
Based on the shape factors, the exomere-sized (ρ =0.96) and small exosome-sized 
(60-80 nm, ρ=0.95) platelet-derived EVs resembled each other in shape even though 
exosomes have lipid bilayer, opposite to exomeres.18 Larger exosome-sized platelet-
derived EVs on the other hand were closer to ideal homogeneous spheres in shape 
based on their shape factor (ρ =0.85).
The IAC based isolation was expanded to isolate also the CD9+ EVs in addition to the
CD61+ EVs by immobilizing anti-CD9 on the monolithic CIM disks. The anti-CD9 was 
selected as an antibody to capture EVs of more “classical” exosome characteristics 
to compare them to those obtained with the anti-CD61 disk, due to presence of CD9 
in the western blots of the CD61+ EV isolates (Figure 19A). Both the CD9+ and the 
CD61+ EVs were isolated from 250 μL of plasma and fractionated with a quick 
fractionation sequence with AsFlFFF with an initial plan to reduce the time required 
for the fractionation. The resulting fractograms (Figure 21) show that the isolates of 
the anti-CD9 gave two times higher raw DLS detector intensities compare to isolates 
from the anti-CD61 disk and size ranges of 30-80 nm. Within this size range, the 
exomere and the small exosome-sized EVs can be found. It was also logical that 
more of the CD9+ EVs were found in the plasma due to CD9 being a common marker 
for the exosome-sized EVs from different sources of origin, while the CD61+ EVs
would represent mainly the EVs originating from the platelets. In addition, the platelet-
derived EVs have not been commonly detected in the size range of exosomes and 
below, since they are conventionally found in the size range of microvesicles (50-
1000 nm). In addition, both isolates had more particles in the size range of exomeres, 
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indicating that the blood is an abundant source of exomere-sized EVs. This has not 
been detected before this thesis, since the studies of exomeres have been mainly 
concentrating on cell cultures.18  
 
Figure 21. Raw flow DLS detector signal (blue and red lines) with Z-average or the 
hydrodynamic diameter, Dh (red and blue circles). Red lines and circles represent 
CD61+ EVs and blue lines and circles represent CD9+ EVs. 
 
Particle yields as determined by the nanoparticle tracking analysis were 
26.5±1.6·1010 mL-1 for the CD61+ EVs and 76.1±3.6·1010 mL-1 for the CD9+ EVs, which 
also complemented the raw DLS detector data showing that there were approximately 
3 times more EVs in the isolates from the anti-CD9 disks. 
5.3.1 Capillary electrophoresis coupled with laser-induced 
fluorescent detection of extracellular vesicle subpopulations 
 
A newly developed CE-LIF method for the detection and the separation of EVs was 
utilized to further study the CD9+ and the CD61+ EVs (Figure 22). The IAC isolation 
method was also compared to more conventional EV separation techniques such as 
UC and SEC for samples of different animal and human origin. Three similar EV 
subpopulations were detected by the CE-LIF (Figure 22) as was detected earlier by 
the AsFlFFF (Figure 20) for the isolates of the IAC method. Overall, the EV isolates 
obtained by the IAC had more peaks and higher fluorescence intensities compared 
to those obtained by other techniques. Significantly (up to 100 times) lower signal in 
relative fluorescence units (RFUs) was obtained especially when comparing to the 
EVs isolated by SEC using two times more starting material (500 μL). The highest 
concentration (based on CE-LIF signal intensity) of the IAC isolated EVs was at 17 
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min. Other subpopulations were found at 10 and 12 min. The peak at 10-12 min 
became more intense for the CD9+ EVs compared to that for the CD61+ EVs. Due to
the lack of reference material, it was not possible to draw conclusions on the precise
size and charge of the EV subpopulations, but since the peak from 13 min onwards
was not found in isolates achieved by other isolation techniques, it could potentially 
be assigned to the exomere-sized EVs isolated by IAC, since other techniques are 
not known to isolate the exomere-sized particles with the isolation parameters 
selected in our study.
The effort was made to get reference material for different sized EVs by combining 
size fractions of the isolates from the runs shown in Figure 21. Diluted fractions from 
the fast AsFlFFF method were lyophilized and analyzed with CE-LIF (marked with 
dashed lines for the exomere-sized EVs of size <50 nm in Figure 22). In addition, we
could confirm that the AsFlFFF fractionated EVs were still preserved even after the
lyophilization. However, it was noticed that the faster AsFlFFF method was not 
suitable to separate subpopulations sufficiently compared to the slower one (Figure 
20). The effect of the two elution solutions, ammonium hydroxide and carbonate-
bicarbonate solution, used in IAC on the LIF were also studied. The CFDA-SE
labeling was less efficient with ammonium hydroxide-based EV isolates due to 
conversion of the CFDA-SE into side products in the presence of ammonium/amine 
groups. Thus, we could confirm that the carbonate-bicarbonate solution was the best




Figure 22. CE-LIF electropherograms for fluorescently labeled EVs (matrix removal 
with Exosome Spin Columns (MW 3000)). The EVs were purified from bovine milk,
pony plasma, pony serum, and human plasma. BGE: Tris / CHES (I= 90 mM, pH 8.4). 
EVs isolated with the IAC are represented by continuous lines, while the dashed lines 
represent the EV < 50 nm fractions further fractionated with the AsFIFFF after the 
IAC elution step. The CE-LIF of the EVs (in PBS) derivatized with the CFDA-SE, using 
ISF BGE Tris / CHES (pH 8.4). Other CE conditions were: uncoated fused silica 
capillary with I.D. of 50 μm, effective length (Leff) of 50.2 cm and total length (Ltot) of 
60.2 cm, applied voltage: +25 kV, and hydrodynamic injection at 3.4 kPa for 2 min. 






5.4  Development of on-line immunoaffinity 
chromatography - asymmetrical flow field-flow 
fractionation system 
 
Success with the IAC and the AsFlFFF methods led us to further improve the system 
by combining them on-line (Figure 23) for the isolation and fractionation of 
subpopulations of the biomacromolecules. This on-line system had an automated 
sample introduction to the monolithic disk (Figure 23A), including the control of the 
isolation and washing of the monolithic disk (Figure 23B), injection of the isolated 
sample to the AsFlFFF for the size-based fractionation (Figure 23C), and 
characterization by different detectors (Figure 23D). 
 
Figure 23. Automated on-line system for the isolation of nanosized 
biomacromolecules. The system consisted of (A) a selection valve for controlling the 
isolation process, (B) a monolithic column for the IAC, (C) an automated six port valve 
for injection to the AsFlFFF, and (D) the AsFlFFF with UV, MALS, DAD, and DLS 
detectors, and a fraction collector. 
The system was designed to isolate and fractionate the EVs and the lipoproteins from 
one of the most complex biofluids, blood plasma, but the system is also applicable to 
less complex biofluids. With this automated on-line system aggregation,122,299 
operator dependent errors,300 oxidation, shear and mechanical stress, and 
contamination,301 can be reduced or even eliminated. The automated on-line system 
allowed significant reduction in time with less man power. In addition, the quality of 




5.4.1 Application of the on-line system to isolation and 
fractionation of subpopulation of lipoproteins and 
extracellular vesicles 
 
The initial optimization of the on-line IAC-AsFlFFF system was carried out with the 
anti-apoB-100 disk that was selected based on studies in Paper I and since it was 
easier to detect lipoproteins than EVs due to their higher amounts in human plasma. 
UC-isolated LDL was used for the optimization of the six-port valve timer that 
connected IAC to AsFlFFF. The time 125 s (Figure 24) was used for all the 
subsequent experiments. It was already at this stage noticed that the UV peak areas 
gave good repeatabilities of 0.3-6.6%. 

















Six port valve timer (s)
 
Figure 24. Times for a six-port valve timer of IAC isolated 100 μg/mL LDL eluted in 
AsFlFFF based on UV 280 nm peak areas (n=25). 
 
Then the next step was to get the best recovery for apoB-100 containing lipoproteins 
with the focus being on small-dense LDL (sdLDL). UC-isolated LDL (1 mL, c=250 
μg/mL) was isolated and fractionated in triplicate (RSD 6.6%) with the IAC-AsFlFFF 
system by the anti-apoB-100 disk. The density range of these LDL isolates were 
1.019–1.050 g/mL, they excluded very small sdLDL that can be found at the densities 
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of 1.050-1.063 g/mL.189,222,223 The IAC-AsFlFFF isolated and fractionated LDL (Figure 
25A, 10-15 min) had a hydrodynamic diameter size range of 24-28 nm confirming that 
the sdLDL and especially very small sdLDL were no present in the UC-isolated 
sample (the size range for sdLDLs is according to different techniques 16.7-25.8 
nm214–217). The DAD detector could also detect carotenoids (11-18 min) that were 
present in the core of the LDL (430-500 nm).299 This emphasized the importance of 
DAD in the IAC-AsFlFFF system as a quality control detector for the EVs, since the 
conventional isolation methods often yield EVs with LDL contaminants.  Fractionated 
LDL isolates were also assayed with DC protein assay and showed 99.6% recovery, 
and the samples contained 0.43 ± 0.01 mg of cholesterol.  
The system applied to isolating the apoB-100 containing lipoproteins from human 
plasma (Figure 25B) gave excellent RSDs for UV peak areas (0.84%, n=3) and size 
ranges covered all apoB-100 lipoproteins (LDL, IDL, and VLDL) and excluded other 
lipoproteins such as HDL. Most importantly the system was able to isolate sdLDLs 
from the human plasma (retention time 11-12 min).  
 
Figure 25. IAC-AsFlFFF analysis profiles after fractionating the anti-apoB-100 
monolithic disk isolates. Technical replicates (n = 3) of raw flow DLS data, the 
hydrodynamic diameter (dots as Z-Average) on the top, and isoabsorbance plot of 
selected runs in the bottom, (A) of preisolated LDLs by UC and (B) apoB-100 
containing lipoproteins isolated from human plasma. 
 
The sdLDL fraction can be used e.g., for further functional studies where the intact 
particles are needed. The carotenoids were also present in a broader area in the 
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isoabsorbance plot indicating that also bigger particles (IDL and VLDL) in size up to 
95 nm contained carotenoids (Figure 25B, 10-15 min).
The on-line system was then applied to study subpopulations of EVs (Figure 26). Two 
separate disks were prepared: anti-CD9 and anti-CD61. The CD9 antibody was 
utilized to isolate the CD9+ EVs in the size range of exosomes,1,302,303 while the CD61 
was used to isolate the platelet-derived CD61+ EVs. Based on our results with anti-
CD9 and anti-CD61 disks from Papers II and III, we divided the subpopulations to the 
following size groups: <50 nm for the size range of exomeres,18 and 50–80 and 80–
120 nm for the size ranges of exosomes. These size ranges were suitable in IAC for 
the monolithic disk columns that had a pore size diameter of 1.3 μm.
We could immediately identify that our EV fractions did not contain contaminating 
lipoproteins since no carotenoids were detected by the DAD as shown in Figure 26A.
The concentrations of EVs in the exosomal size range were higher for the isolates of 
the anti-CD9 disk (Figure 26B). Both the CD9+ and the CD61+ EVs also contained 
significant concentrations of exomere-sized EVs (<50 nm). The on-line system could 
reproducibly (RSD of UV-peak areas for CD9+ EVs were 2.9% and CD61+ EVs 4.2%)
isolate and fractionate the EV subpopulations, which were also detected with FESEM 
(Figure 26C) with size ranges that agreed with hydrodynamic radiuses obtained by 
the DLS detector (Figure 26A). Surprisingly, the exomere-sized EVs that have been
reported to contain low amounts of tetraspanin CD9 and integrins like CD6118 were 
detected from both plasma isolates in relatively high amounts. The reason for this 
was that the samples in the other studies originated from cell lines and cell cultures,
whereas in this work, the monolithic IAC disks isolated every type of exomere-sized 
CD9+ and CD61+ EVs that ended up in the blood circulation. Thus, the results show
relatively high exomere-sized EV concentrations for both of the disks utilized in the 
thesis. The fractionated samples were pooled to their assigned size ranges and their 
zeta potentials were studied (Figure 27). We found that the CD9+ < 50 nm EVs had a 
mean charge of −14.1 mV, while for the exosome-sized subpopulations 50-80 nm 
and 80-120 nm, the corresponding values were -16.2 mV and -16.9 mV, respectively.
The CD61+ < 50 nm subpopulation had a mean charge of −15.1, and −14.2 mV for 
the exosome-sized subpopulations of 50–80 nm, and −16.6 mV for 80–120 nm. The 
results agreed with the zeta potentials reported by other groups for the cell culture




Figure 26. IAC-AsFlFFF analysis profiles after fractionating the CD9+ and CD61+ EV 
isolates. Technical replicates (n = 3) of raw flow DLS data, the hydrodynamic 
diameter (dots as Z-Average) on top, and (A) isoabsorbance plot of the selected run 
at the bottom. (B) Overlaid UV spectra (280 nm) from the technical replicates, and 




Figure 27. Zeta potential of the CD9+ and the CD61+ EV subpopulations. 
 
The IAC-AsFlFFF system proved to be faster and more selective for the isolation and 
fractionation of subpopulations of lipoproteins and EVs compared to conventional 
isolation techniques and methods,66 most of which are not even capable of isolating 
the subpopulations. The system was able to process 38 lipoprotein samples / 24h 
and 18 EV samples / 24h with the optimized time program. The MALS and DLS 
detectors coupled on-line with the AsFlFFF were able to give real time size 
information of the fractions, the UV detector was used for concentration, and DAD for 
qualitative information on the contaminants. The system was also highly repeatable, 
with low oxidation, contamination, and sample losses, resulting in productivity 
increase for the instruments and the personnel. The quality of the data was also 
improved significantly compared to the systems used in Papers II and III. 
The isolated CD9+ and CD61+ EV subpopulations were studied further to find out the 
composition of the free amino acids and glucose found inside the subpopulations. 
EVs carry amino acids and other small metabolites304 that are involved in 
physiological activities, and thus the analyzed concentrations might have diagnostic 
relevance in addition to fundamental understanding of the role of the EVs in the 
physiology. The study was done by extracting the free amino acids and glucose and 
analyzing them with HILIC-MS/MS (Figure 28). The differences between the CD9+ 
and the CD61+ EV subpopulations are found in Figure 28A. From the free amino 
acids, Ser was the most abundant. Ser is known to be important in the membrane 
lipid synthesis of e.g., sphingolipids and phosphatidylserine that have also been found 
in exosomal membranes.305,306  The small exosomes (50-80 nm) of the CD61+ EVs 
contained the highest concentrations of free amino acids compared to the other 
subpopulations of the CD61+ EVs. For the CD9+ EVs the highest concentrations were 
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found in the large exosomes (80-120 nm). In addition, regardless of antibody used 
for the isolation, the Ser content of the exomere-sized EVs (<50 nm) was smallest,
supporting the finding (Zhang et al.18) that exomeres do not have a lipid bilayer.
With the principal component analysis (PCA, Figure 28B) it was found that there were
clear differences between the CD9+ and the CD61+ EVs. While with linear 
discriminant analysis (LDA, Figure 28C), with 93% samples correctly classified, it was 
found that the differences between the CD9+ and the CD61+ EVs were due to the
following amino acids: Ala, Gly, Lys, Phe, Ser, Thr, and Val. The CD9+ EVs had lower 
levels of Ala, Gly, and Thr, compared to the CD61+ EVs. This suggested that the 
CD61+ EVs may take part in gluconeogenesis, since amino acids Ala, Cys, Gly, Ser, 
and Thr can be directly converted to pyruvate.307 The Ala and the Gly are also 
important in immune response inhibiting apoptosis,308 and act as anti-inflammatory 
and immunomodulatory agents.309 Since the CD61+ EVs originated from platelets, 
these findings further support their potential role in the inflammation and the
immunity-related tasks after being released from platelets into the circulation.
Irrespective of the origin of the EVs, the small exosome-sized EV subpopulations (50-
80 nm) contained Ala, Gly, Ser, and Thr (Figure 28D), suggesting that these 
subpopulation sizes are preferred in the gluconeogenesis related tasks.
Even further analysis of differences between subpopulations among the CD9+ and
the CD61+ EVs were investigated (Figures 28E-H). Here as well we detected
differences with the PCA (Figures 28 E and G) and the LDA models, with samples 
90% (for CD9+) and 100% (for CD61+) classified. In the CD61+ EVs Cys, Gly, Phe, 
Ser, and Thr were those free amino acids contributing to the differences between the 
subpopulations (highest levels in the 50-80 nm subpopulation), while Asn, Cit, Glu, 
Lys, Phe, and Ser were the amino acids contributing to the CD9+ EVs (highest levels 
in the 80-120 nm subpopulation). The differences between compositions of the 
subpopulations also reflect their distinct origins.
The glucose levels of the EVs were also studied. All CD61+ EV subpopulations 
contained glucose in the concentration range of pmol/mL and are also possibly 
involved in the gluconeogenesis based on their free amino acid composition. In the 
CD9+ EVs, glucose was found only in the 50-80 nm subpopulation, which was also 
the preferred size for the gluconeogenesis based on the free amino acid composition
(Figure 28D). With on-line IAC-AsFlFFF it was thus possible to isolate and fractionate 
the exomere- and the exosome-sized EVs for further studies. The on-line system is a
viable tool for the study of the role of EV subpopulations in human physiology. The 
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fractions can potentially also be produced for therapeutic purposes. Additional 
applications are linked to the biomarker and composition studies of different 
biomacromolecules. 
 
Figure 28. Multivariate analysis of amino acids found in the CD61+ and the CD9+ EV 
subpopulations. (A) Heat map visualization of amino acids corresponding to their 
normalized concentrations (ng/mL per μg/mL of total protein). (B) Scoring plot of PCA 
analysis showing differences between CD61+ and CD9+ EVs. (C) Discriminant 
analysis of differences between amino acids found in CD61+ and CD9+ EVs. (D) 
Discriminant analysis of differences between amino acids found between different 
sizes of combined EV subpopulations. (E) Scoring plot of PCA analysis revealing 
differences between subpopulations of different sizes of CD61+ EVs. (F) Discriminant 
analysis of differences between amino acids found between CD61+ EV 
subpopulations. (G) Scoring plot of PCA analysis revealing differences between 
subpopulations of different sizes of CD9+ EVs. (H) Discriminant analysis of 





The aim of this doctoral thesis was to develop methods and techniques for the 
isolation of subpopulations of lipoproteins and EVs from human plasma. Antibody-
antigen interactions (immunoaffinity) were exploited to capture these 
biomacromolecules, by utilizing carefully clarified antibody-antigen interaction 
information. The final target was to have fast, reliable, and versatile methods that can 
be easily automated for minute sample amounts.
PF-ACE and QCM were employed to study interactions between the anti-apoB-100 
monoclonal antibody and apoB-100 containing lipoprotein subpopulations. The PF-
ACE was combined with AED calculations and the QCM with Interaction Maps to
successfully study the affinity, kinetics, and thermodynamics of the anti-apoB-100 
mAb and apoB-100 containing lipoprotein complex formation. With the 
thermodynamic studies we could demonstrate that LDL and the anti-apoB-100 Mab 
interactions were enthalpy-driven. The interaction maps were for the first time used
to visualize the QCM data, and they provided insight into the association and 
dissociation phenomena behind the antigen-antibody complex formation at different 
temperatures. It was found that the dissociation rate constant increased 10-folds from 
25 °C to 40 °C. No temperature effect on the association rate constant was noticed.
The interaction maps could distinguish two distinct kinetic parameters for the 
interaction of IDL-VLDL and the anti-apoB-100 Mab. PF-ACE with the AED
calculations confirmed that the interactions were homogenous with only a single site 
adsorption model needed to explain the complex formation. In addition, the results 
obtained with PF-ACE agreed well with those achieved with QCM, indicating that both 
techniques are reliable in the biomolecular interaction studies.
Next step was to develop IAC method to isolate platelet-derived (CD61+) EV
subpopulations. For the first time polymeric monolithic disk columns were used for 
the IAC-based isolation of the EVs and their subpopulations from human plasma. The 
anti-CD61 CIM disks enabled fast isolation, carried out in under 10 min at a flow rate 
of 1.0 mL/min with 5 mL of diluted plasma sample. However, lower flow rates were
found to be optimal, since they resulted in higher yields. It was also possible to 
regenerate the disk for even hundreds of isolations reducing the relative cost of the 
disk. For higher EV yields, the monolithic disk can be loaded with a higher amount of 
the antibody or a better optimization scheme is needed to select the best plasma 
sample volumes and flow rates. For some specific applications of the EV isolates, an
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additional concentrating step will be needed. The isolates were studied further with 
AsFlFFF combined with MALS and flow DLS detectors, and for the first time the 
evidence for the existence of platelet-derived EVs in the size range of exomeres and 
exosomes (<100 nm) was obtained.
After successful implementation of the IAC for the EV isolation, the technique was 
compared with UC and SEC. The isolated CD9+ and CD61+ EVs in the size range of 
exomeres and exosomes were labeled and characterized with the newly developed 
CE-LIF method. The mass/charge-based separation of EVs was achieved by CE-LIF.
The EV isolates obtained by IAC gave more peaks and higher fluorescence intensities 
compared to those achieved by other techniques. Especially the EVs isolated by 
SEC, having two times more starting material (500 μL of plasma), gave significantly 
(up to 100 times) lower signal in relative fluorescence units (RFUs). The IAC isolates
also had higher RFUs compared to those isolated by UC.
Positive results achieved with IAC and AsFlFFF inspired us to successfully combine 
these techniques into an automated on-line IAC-AsFlFFF system for isolation and 
fractionation of exomere- and exosome-sized EVs, and apoB-100 containing 
lipoprotein subpopulations. The system was equipped with DAD that could e.g.,
detect if the EV subpopulation isolates were lipoprotein-free. With the on-line coupled 
IAC-AsFlFFF it was possible to have fast, reliable, and reproducible isolation and 
fractionation of challenging biomacromolecules from human plasma with a high purity 
and high yields of subpopulations. The system could process 18-38 samples in 24h 
with only minor operator involvement. In addition, AsFlFFF allowed gentle 
fractionation of lipoproteins and EVs. We could detect EV subpopulations in the size 
range of exomeres and exosomes, based on DLS and MALS data and confirmed by
FESEM. The system was also able to fractionate sdLDL from other LDL subclasses.
The surface charges of exomere-sized EV subpopulations were in agreement with 
the zeta potentials found in the literature for exomeres. Finally, the pooled EV 
fractions were subjected to metabolite (amino acid and sugar) composition analysis 
for CD9+ and CD61+ EV subpopulations. The statistical analysis with PCA and LDA 
revealed that there were significant differences between the origins of EVs and 
between subpopulations. The on-line IAC-AsFlFFF system is applicable for the 
isolation of any biomacromolecules of interest and their subpopulations if the suitable 
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